Document:

Exhibit 10.9

       

      DISC MEDICINE, INC.

      

      

      2017 STOCK OPTION AND GRANT PLAN

       

      SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

       

      The name of the plan is the Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of
        Disc Medicine, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Subsidiaries, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a
        proprietary interest in the Company.

       

      The following terms shall be defined as set forth below:

       

      “Affiliate” of any Person means a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with the first
        mentioned Person. A Person shall be deemed to control another Person if such first Person possesses directly or indirectly the power to direct, or cause the direction of, the management and policies of the second Person, whether through the
        ownership of voting securities, by contract or otherwise.

       

      “Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options,
        Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units or any combination of the foregoing.

       

      “Award Agreement” means a written or electronic agreement setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Agreement may contain
        terms and conditions in addition to those set forth in the Plan; provided, however, in the event of any conflict in the terms of the Plan and the Award Agreement, the terms of the Plan shall govern.

       

      “Board” means the Board of Directors of the Company.

      

      

      “Cause” shall have the meaning as set forth in the Award Agreement(s). In the case that any Award Agreement does not contain a definition of “Cause,” it shall mean (i) the
        grantee’s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business; (ii) the grantee’s
        commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the grantee’s failure to perform his assigned duties and responsibilities to the reasonable satisfaction of the Company which failure
        continues, in the reasonable judgment of the Company, after written notice given to the grantee by the Company; (iv) the grantee’s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company;
        or (v) the grantee’s material violation of any provision of any agreement(s) between the grantee and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions.

      

      

      
        
          

      

      
      “Chief Executive Officer” means the Chief Executive Officer of the Company or, if there is no Chief Executive Officer, then the President of the Company.

       

      “Code” means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.

      

      

      “Committee” means the Committee of the Board referred to in Section 2.

      

      

      “Consultant” means any natural person that provides bona fide services to the Company (including a Subsidiary), and such services are not in connection with the offer or sale
        of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

       

      “Disability” means “disability” as defined in Section 422(c) of the Code.

       

      “Effective Date” means the date on which the Plan is adopted as set forth on the final page of the Plan.

       

      “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

       

      “Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the Committee based on the reasonable application of a
        reasonable valuation method not inconsistent with Section 409A of the Code. If the Stock is admitted to trade on a national securities exchange, the determination shall be made by reference to the closing price reported on such exchange. If there
        is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. If the date for which Fair Market Value is determined is the first day when trading prices for
        the Stock are reported on a national securities exchange, the Fair Market Value shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s Initial Public Offering.

      

      

      “Good Reason” shall have the meaning as set forth in the Award Agreement(s). In the case that any Award Agreement does not contain a definition of “Good Reason,” it shall mean
        (i) a material diminution in the grantee’s base salary except for across-the-board salary reductions similarly affecting all or substantially all similarly situated employees of the Company or (ii) a change of more than 50 miles in the geographic
        location at which the grantee provides services to the Company, so long as the grantee provides at least 90 days notice to the Company following the initial occurrence of any such event and the Company fails to cure such event within 30 days
        thereafter.

       

      

      “Grant Date” means the date that the Committee designates in its approval of an Award in accordance with applicable law as the date on which the Award is granted, which date
        may not precede the date of such Committee approval.

       

      “Holder” means, with respect to an Award or any Shares, the Person holding such Award or Shares, including the initial recipient of the Award or any Permitted Transferee.

       

      

      
        2

        
          

      

      “Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code.

      

      

      “Initial Public Offering” means the consummation of the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities
        Act covering the offer and sale by the Company of its equity securities, as a result of or following which the Stock shall be publicly held.

       

      “Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option.

      

      

      “Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5.

       

      “Permitted Transferees” shall mean any of the following to whom a Holder may transfer Shares hereunder (as set forth in Section 9(a)(ii)(A)): the Holder’s child, stepchild,
        grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the
        Holder’s household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons control the management of assets, and any other entity in which these
        persons own more than fifty percent of the voting interests; provided, however, that any such trust does not require or permit distribution of any Shares during the term of the Award Agreement unless
        subject to its terms. Upon the death of the Holder, the term Permitted

      Transferees shall also include such deceased Holder’s estate, executors, administrators, personal representatives, heirs, legatees and distributees, as the case may be.

       

      “Person” shall mean any individual, corporation, partnership (limited or general), limited liability company, limited liability partnership, association, trust, joint venture,
        unincorporated organization or any similar entity.

       

      “Restricted Stock Award” means Awards granted pursuant to Section 6 and “Restricted Stock” means Shares issued pursuant to such
        Awards.

       

      “Restricted Stock Unit” means an Award of phantom stock units to a grantee, which may be settled in cash or Shares as determined by the Committee, pursuant to Section 8.

      

      

      “Sale Event” means the consummation of (i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially all of the assets of the Company on a
        consolidated basis to an unrelated person or entity, (iii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the
        outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related
        transactions by a Person or group of Persons, or (v) any other acquisition of the business of the Company, as determined by the Board; provided, however, that the Company’s Initial Public Offering, any
        subsequent public offering or another capital raising event, or a merger effected solely to change the Company’s domicile shall not constitute a “Sale Event.”

       

      

      
        3

        
          

      

      “Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder.

      

      

      “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

      

      

      “Service Relationship” means any relationship as a full-time employee, part-time employee, director or other key person (including Consultants) of the Company or any Subsidiary
        or any successor entity (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual’s status changes from full-time employee to part- time employee or Consultant).

      

      

      “Shares” means shares of Stock.

       

      “Stock” means the Common Stock, par value $0.0001 per share, of the Company. “Subsidiary” means any corporation or other entity (other than the Company) in which the Company has more than a 50 percent interest, either directly or indirectly.

      

      

      “Ten Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined
        voting power of all classes of stock of the Company or any parent of the Company or any Subsidiary.

       

      “Termination Event” means the termination of the Award recipient’s Service Relationship with the Company and its Subsidiaries for any reason whatsoever, regardless of the
        circumstances thereof, and including, without limitation, upon death, disability, retirement, discharge or resignation for any reason, whether voluntarily or involuntarily. The following shall not constitute a Termination Event: (i) a transfer to
        the service of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another Subsidiary or (ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the
        Committee, if the individual’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing.

       

      “Unrestricted Stock Award” means any Award granted pursuant to Section 7 and “Unrestricted Stock” means Shares issued pursuant to such
        Awards.

      

      

      SECTION 2. ADMINISTRATION OF PLAN; COMMITTEE AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS

       

      (a)          Administration of Plan. The Plan shall be administered by the Board, or at the discretion of the Board, by a committee of the Board, comprised of not less than two directors. All references herein
        to the “Committee” shall be deemed to refer to the group then responsible for administration of the Plan at the relevant time (i.e., either the Board of Directors or a committee or committees of the Board, as applicable).

       

      (b)          Powers of Committee. The Committee shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:

       

      

      
        4

        
          

      

      (i)          to select the individuals to whom Awards may from time to time be granted;

      

      

      
        (ii)          to determine the time or times of grant, and the amount, if any, of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards,
          Restricted Stock Units, or any combination of the foregoing, granted to any one or more grantees;

      

      
         

        (iii)          to determine the number of Shares to be covered by any Award and, subject to the provisions of the Plan, the price, exercise price, conversion ratio or other price relating thereto;

         

        (iv)          to determine and, subject to Section 12, to modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award,
          which terms and conditions may differ among individual Awards and grantees, and to approve the form of Award Agreements;

        

        

        
          (v)          to accelerate at any time the exercisability or vesting of all or any portion of any Award;

        

        

        

        
          (vi)          to impose any limitations on Awards, including limitations on transfers, repurchase provisions and the like, and to exercise repurchase rights or obligations;

        

        

        

        (vii)          subject to Section 5(a)(ii) and any restrictions imposed by Section 409A, to extend at any time the period in which Stock Options may be exercised; and

        

        

        (viii)          at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and
          provisions of the Plan and any Award (including Award Agreements); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the
          administration of the Plan.

         

        All decisions and interpretations of the Committee shall be binding on all persons, including the Company and all Holders.

         

        (c)          Award Agreement.  Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award.

         

        (d)          Indemnification. Neither the Board nor the Committee, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made
          in good faith in connection with the Plan, and the members of the Board and the Committee (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or
          expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s governing documents, including its certificate of incorporation or bylaws, or any
          directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.

      

      

      
        5

        
          

      

      (e)          Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and any Subsidiary operate or have
        employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries, if any, shall be covered by the Plan; (ii) determine which individuals, if any,
        outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify
        exercise procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to the Plan as appendices); provided, however,
        that no such subplans and/or modifications shall increase the share limitation contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain
        approval or comply with any local governmental regulatory exemptions or approvals.

      

      

      SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS AND OTHER TRANSACTIONS; SUBSTITUTION

      

      

      (a)          Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 710,045 Shares, subject to adjustment as provided in

      Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated
        (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such
        overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 7,100,450 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be
        authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 710,045 Shares shall be granted to any one individual in
        any calendar year period.

       

      (b)          Changes in Stock. Subject to Section 3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change
        in the Company’s capital stock, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional Shares or new or different shares or other securities of
        the Company or other non-cash assets are distributed with respect to such Shares or other securities, in each case, without the receipt of consideration by the Company, or, if, as a result of any merger or consolidation, or sale of all or
        substantially all of the assets of the Company, the outstanding Shares are converted into or exchanged for other securities of the Company or any successor entity (or a parent or subsidiary thereof), the Committee shall make an appropriate and
        proportionate adjustment in (i) the maximum number of Shares reserved for issuance under the Plan, (ii) the number and kind of Shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per
        Share subject to each outstanding Award, and (iv) the exercise price for each Share subject to any then outstanding Stock Options under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of
        Stock Options) as to which such Stock Options remain exercisable. The Committee shall in any event make such adjustments as may be required by Section 25102(o) of the California Corporation Code and the rules and regulations promulgated thereunder.
        The adjustment by the Committee shall be final, binding and conclusive. No fractional Shares shall be issued under the Plan resulting from any such adjustment, but the Committee in its discretion may make a cash payment in lieu of fractional
        shares.

      

      

      
        6

        
          

      

      
        (c)          Sale Events.

      

       

      
        (i)          Options.

      

       

      

      

      (A)          In the case of and subject to the consummation of a Sale Event, the Plan and all outstanding Options issued hereunder shall terminate upon the effective time of any such Sale Event
        unless assumed or continued by the successor entity, or new stock options or other awards of the successor entity or parent thereof are substituted therefor, with an equitable or proportionate adjustment as to the number and kind of shares and, if
        appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder and/or pursuant to the terms of any Award Agreement).

       

      (B)          In the event of the termination of the Plan and all outstanding Options issued hereunder pursuant to Section 3(c), each Holder of Options shall be permitted, within a period of time
        prior to the consummation of the Sale Event as specified by the Committee, to exercise all such Options which are then exercisable or will become exercisable as of the effective time of the Sale Event; provided,
          however, that the exercise of Options not exercisable prior to the Sale Event shall be subject to the consummation of the Sale Event.

       

      (C)          Notwithstanding anything to the contrary in Section 3(c)(i)(A), in the event of a Sale Event, the Company shall have the right, but not the obligation, to make or provide for a cash
        payment to the Holders of Options, without any consent of the Holders, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the value as determined by the Committee of the consideration payable per share of
        Stock pursuant to the Sale Event (the “Sale Price”) times the number of Shares subject to outstanding Options being cancelled (to the extent then vested and exercisable, including by reason of acceleration in connection with such Sale Event, at
        prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding vested and exercisable Options.

      

      

      
        (ii)          Restricted Stock and Restricted Stock Unit Awards.

      

       

      (A)          In the case of and subject to the consummation of a Sale Event, all unvested Restricted Stock and unvested Restricted Stock Unit Awards (other than those becoming vested as a result of
        the Sale Event) issued hereunder shall be forfeited immediately prior to the effective time of any such Sale Event unless assumed or continued by the successor entity, or awards of the successor entity or parent thereof are substituted therefor,
        with an equitable or proportionate adjustment as to the number and kind of shares subject to such awards as such parties shall agree (after taking into account any acceleration hereunder and/or pursuant to the terms of any Award Agreement).

       

      

      
        7

        
          

      

      (B)          In the event of the forfeiture of Restricted Stock pursuant to Section 3(c)(ii)(A), such Restricted Stock shall be repurchased from the Holder thereof at a price per share equal to the
        original per share purchase price paid by the Holder (subject to adjustment as provided in Section 3(b)) for such Shares.

      

      

      (C)          Notwithstanding anything to the contrary in Section 3(c)(ii)(A), in the event of a Sale Event, the Company shall have the right, but not the obligation, to make or provide for a cash
        payment to the Holders of Restricted Stock or Restricted Stock Unit Awards, without consent of the Holders, in exchange for the cancellation thereof, in an amount equal to the Sale Price times the number of Shares subject to such Awards, to be paid
        at the time of such Sale Event or upon the later vesting of such Awards.

      

      

      SECTION 4. ELIGIBILITY

      

      

      Grantees under the Plan will be such full or part-time officers and other employees, directors, Consultants and key persons of the Company and any Subsidiary who are selected from time to time by the Committee in its
        sole discretion; provided, however, that Awards shall be granted only to those individuals described in Rule 701(c) of the Securities Act.

       

      SECTION 5. STOCK OPTIONS

      

      

      Upon the grant of a Stock Option, the Company and the grantee shall enter into an Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the Committee, and such terms and
        conditions may differ among individual Awards and grantees.

       

      Stock Options granted under the Plan may be either Incentive Stock Options or Non- Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary
        that is a “subsidiary corporation” within the meaning of

       

      Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.

       

      (a)          Terms of Stock Options. The Committee in its discretion may grant Stock Options to those individuals who meet the eligibility requirements of Section 4. Stock Options shall be subject to the
        following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable.

       

      (i)          Exercise Price. The exercise price per share for the Shares covered by a Stock Option shall be determined by the Committee at the time of grant but shall not be less than 100 percent of the Fair
        Market Value on the Grant Date. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price per share for the Shares covered by such Incentive Stock Option shall not be less than 110 percent of the Fair
        Market Value on the Grant Date.

       

      

      
        8

        
          

      

      (ii)          Option Term. The term of each Stock Option shall be fixed by the Committee, but no Stock Option shall be exercisable more than ten years from the Grant Date. In the case of an Incentive Stock
        Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the Grant Date.

      

      

      (iii)          Exercisability; Rights of a Stockholder. Stock Options shall become exercisable and/or vested at such time or times, whether or not in installments, as shall be determined by the Committee at or
        after the Grant Date. The Award Agreement may permit a grantee to exercise all or a portion of a Stock Option immediately at grant; provided that the Shares issued upon such exercise shall be subject to restrictions and a vesting schedule identical
        to the vesting schedule of the related Stock Option, such Shares shall be deemed to be Restricted Stock for purposes of the Plan, and the optionee may be required to enter into an additional or new Award Agreement as a condition to exercise of such
        Stock Option. An optionee shall have the rights of a stockholder only as to Shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. An optionee shall not be deemed to have acquired any Shares unless and until a
        Stock Option shall have been exercised pursuant to the terms of the Award Agreement and this Plan and the optionee’s name has been entered on the books of the Company as a stockholder.

      

      

      (iv)          Method of Exercise. Stock Options may be exercised by an optionee in whole or in part, by the optionee giving written or electronic notice of exercise to the Company, specifying the number of
        Shares to be purchased. Payment of the purchase price may be made by one or more of the following methods (or any combination thereof) to the extent provided in the Award Agreement:

      

      

      (A)          In cash, by certified or bank check, by wire transfer of immediately available funds, or other instrument acceptable to the Committee;

       

      (B)          If permitted by the Committee, by the optionee delivering to the Company a promissory note, if the Board has expressly authorized the loan of funds to the optionee for the purpose of
        enabling or assisting the optionee to effect the exercise of his or her Stock Option; provided, that at least so much of the exercise price as represents the par value of the Stock shall be paid in cash if required by state law;

       

      (C)          If permitted by the Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded), through the delivery (or attestation to the ownership) of
        Shares that have been purchased by the optionee on the open market or that are beneficially owned by the optionee and are not then subject to restrictions under any Company plan. To the extent required to avoid variable accounting treatment under
        ASC 718 or other applicable accounting rules, such surrendered Shares if originally purchased from the Company shall have been owned by the optionee for at least six months. Such surrendered Shares shall be valued at Fair Market Value on the
        exercise date;

       

      

      
        9

        
          

      

      (D)          If permitted by the Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded), by the optionee delivering to the Company a properly executed
        exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the
        purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Committee shall prescribe as a condition of such payment procedure; or

       

      (E)          If permitted by the Committee, and only with respect to Stock Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the
        number of Shares issuable upon exercise by the largest whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price.

      

      

      Payment instruments will be received subject to collection. No certificates for Shares so purchased will be issued to the optionee or, with respect to uncertificated Stock, no transfer to the optionee on the records of
        the Company will take place, until the Company has completed all steps it has deemed necessary to satisfy legal requirements relating to the issuance and sale of the Shares, which steps may include, without limitation, (i) receipt of a
        representation from the optionee at the time of exercise of the Option that the optionee is purchasing the Shares for the optionee’s own account and not with a view to any sale or distribution of the Shares or other representations relating to
        compliance with applicable law governing the issuance of securities, (ii) the legending of the certificate (or notation on any book entry) representing the Shares to evidence the foregoing restrictions, and (iii) obtaining from optionee payment or
        provision for all withholding taxes due as a result of the exercise of the Option. The delivery of certificates representing the shares of Stock (or the transfer to the optionee on the records of the Company with respect to uncertificated Stock) to
        be purchased pursuant to the exercise of a Stock Option will be contingent upon (A) receipt from the optionee (or a purchaser acting in his or her stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
        price for such Shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws and (B) if required by the Company, the optionee shall have entered into any stockholders agreements or other
        agreements with the Company and/or certain other of the Company’s stockholders relating to the Stock. In the event an optionee chooses to pay the purchase price by previously-owned Shares through the attestation method, the number of Shares
        transferred to the optionee upon the exercise of the Stock Option shall be net of the number of Shares attested to.

       

      (b)          Annual Limit on Incentive Stock Options. To the extent required for “incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the Grant
        Date) of the Shares with respect to which Incentive Stock Options granted under the Plan and any other plan of the Company or its parent and any Subsidiary that become exercisable for the first time by an optionee during any calendar year shall not
        exceed $100,000 or such other limit as may be in effect from time to time under Section 422 of the Code. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.

       

      

      
        10

        
          

      

      SECTION 6. RESTRICTED STOCK AWARDS

       

      (a)          Nature of Restricted Stock Awards. The Committee may, in its sole discretion, grant (or sell at par value or such other purchase price determined by the Committee) to an eligible individual under
        Section 4 hereof a Restricted Stock Award under the Plan. The Committee shall determine the restrictions and conditions applicable to each Restricted Stock Award at the time of grant. Conditions may be based on continuing employment (or other
        Service Relationship), achievement of pre-established performance goals and objectives and/or such other criteria as the Committee may determine. Upon the grant of a Restricted Stock Award, the Company and the grantee shall enter into an Award
        Agreement. The terms and conditions of each such Award Agreement shall be determined by the Committee, and such terms and conditions may differ among individual Awards and grantees.

       

      (b)          Rights as a Stockholder. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee of Restricted Stock shall be considered the record owner of and shall be
        entitled to vote the Restricted Stock if, and to the extent, such Shares are entitled to voting rights, subject to such conditions contained in the Award Agreement. The grantee shall be entitled to receive all dividends and any other distributions
        declared on the Shares; provided, however, that the Company is under no duty to declare any such dividends or to make any such distribution. Unless the Committee shall otherwise determine, certificates evidencing the Restricted
        Stock shall remain in the possession of the Company until such Restricted Stock is vested as provided in subsection (d) below of this Section, and the grantee shall be required, as a condition of the grant, to deliver to the Company a stock power
        endorsed in blank and such other instruments of transfer as the Committee may prescribe.

       

      (c)          Restrictions. Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Award Agreement. Except as may
        otherwise be provided by the Committee either in the Award Agreement or, subject to Section 12 below, in writing after the Award Agreement is issued, if a grantee’s Service Relationship with the Company and any Subsidiary terminates, the Company or
        its assigns shall have the right, as may be specified in the relevant instrument, to repurchase some or all of the Shares subject to the Award at such purchase price as is set forth in the Award Agreement.

       

      (d)          Vesting of Restricted Stock. The Committee at the time of grant shall specify in the Award Agreement the date or dates and/or the attainment of pre-established performance goals, objectives and
        other conditions on which the substantial risk of forfeiture imposed shall lapse and the Restricted Stock shall become vested, subject to such further rights of the Company or its assigns as may be specified in the Award Agreement.

       

      SECTION 7.  UNRESTRICTED STOCK AWARDS

       

      The Committee may, in its sole discretion, grant (or sell at par value or such other purchase price determined by the Committee) to an eligible person under Section 4 hereof an Unrestricted Stock Award under the Plan.
        Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.

       

      

      
        11

        
          

      

      SECTION 8. RESTRICTED STOCK UNITS

       

      (a)          Nature of Restricted Stock Units. The Committee may, in its sole discretion, grant to an eligible person under Section 4 hereof Restricted Stock Units under the Plan. The Committee shall determine
        the restrictions and conditions applicable to each Restricted Stock Unit at the time of grant. Vesting conditions may be based on continuing employment (or other Service Relationship), achievement of pre-established performance goals and objectives
        and/or other such criteria as the Committee may determine. Upon the grant of Restricted Stock Units, the grantee and the Company shall enter into an Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the
        Committee and may differ among individual Awards and grantees. On or promptly following the vesting date or dates applicable to any Restricted Stock Unit, but in no event later than March 15 of the year following the year in which such vesting
        occurs, such Restricted Stock Unit(s) shall be settled in the form of cash or shares of Stock, as specified in the Award Agreement. Restricted Stock Units may not be sold, assigned, transferred, pledged, or otherwise encumbered or disposed of.

      

      

      (b)          Rights as a Stockholder. A grantee shall have the rights of a stockholder only as to Shares, if any, acquired upon settlement of Restricted Stock Units. A grantee shall not be deemed to have
        acquired any such Shares unless and until the Restricted Stock Units shall have been settled in Shares pursuant to the terms of the Plan and the Award Agreement, the Company shall have issued and delivered a certificate representing the Shares to
        the grantee (or transferred on the records of the Company with respect to uncertificated stock), and the grantee’s name has been entered in the books of the Company as a stockholder.

      

      

      
        (c)          Termination. Except as may otherwise be provided by the Committee either in

      

      the Award Agreement or in writing after the Award Agreement is issued, a grantee’s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee’s cessation of Service Relationship with the Company and
        any Subsidiary for any reason.

       

      SECTION 9. TRANSFER RESTRICTIONS; COMPANY RIGHT OF FIRST REFUSAL; COMPANY REPURCHASE RIGHTS

       

      
        (a)          Restrictions on Transfer.

      

       

      (i)          Non-Transferability of Stock Options. Stock Options and, prior to exercise, the Shares issuable upon exercise of such Stock Option, shall not be transferable by the optionee otherwise than by will,
        or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the optionee’s lifetime, only by the optionee, or by the optionee’s legal representative or guardian in the event of the optionee’s incapacity.
        Notwithstanding the foregoing, the Committee, in its sole discretion, may provide in the Award Agreement regarding a given Stock Option that the optionee may transfer by gift, without consideration for the transfer, his or her Non-Qualified Stock
        Options to his or her family members (as defined in Rule 701 of the Securities Act), to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners (to the extent such trusts or partnerships
        are considered “family members” for purposes of Rule 701 of the Securities Act), provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement,
        including the execution of a stock power upon the issuance of Shares. Stock Options, and the Shares issuable upon exercise of such Stock Options, shall be restricted as to any pledge, hypothecation, or other transfer, including any short position,
        any “put equivalent position” (as defined in the Exchange Act) or any “call equivalent position” (as defined in the Exchange Act) prior to exercise.

       

      

      
        12

        
          

      

      (ii)          Shares. No Shares shall be sold, assigned, transferred, pledged, hypothecated, given away or in any other manner disposed of or encumbered, whether voluntarily or by operation of law, unless (i)
        the transfer is in compliance with the terms of the applicable Award Agreement, all applicable securities laws (including, without limitation, the Securities Act), and with the terms and conditions of this Section 9, (ii) the transfer does not
        cause the Company to become subject to the reporting requirements of the Exchange Act, and (iii) the transferee consents in writing to be bound by the provisions of the Plan and the Award Agreement, including this Section 9. In connection with any
        proposed transfer, the Committee may require the transferor to provide at the transferor’s own expense an opinion of counsel to the transferor, satisfactory to the Committee, that such transfer is in compliance with all foreign, federal and state
        securities laws (including, without limitation, the Securities Act). Any attempted transfer of Shares not in accordance with the terms and conditions of this Section 9 shall be null and void, and the Company shall not reflect on its records any
        change in record ownership of any Shares as a result of any such transfer, shall otherwise refuse to recognize any such transfer and shall not in any way give effect to any such transfer of Shares. The Company shall be entitled to seek protective
        orders, injunctive relief and other remedies available at law or in equity including, without limitation, seeking specific performance or the rescission of any transfer not made in strict compliance with the provisions of this Section 9. Subject to
        the foregoing general provisions, and unless otherwise provided in the applicable Award Agreement, Shares may be transferred pursuant to the following specific terms and conditions (provided that with respect to any transfer of Restricted Stock,
        all vesting and forfeiture provisions shall continue to apply with respect to the original recipient):

       

      

      (A)          Transfers to Permitted Transferees. The Holder may transfer any or all of the Shares to one or more Permitted Transferees; provided, however,
        that following such transfer, such Shares shall continue to be subject to the terms of this Plan (including this Section 9) and such Permitted Transferee(s) shall, as a condition to any such transfer, deliver a written acknowledgment to that effect
        to the Company and shall deliver a stock power to the Company with respect to the Shares. Notwithstanding the foregoing, the Holder may not transfer any of the Shares to a Person whom the Company reasonably determines is a direct competitor or a
        potential competitor of the Company or any of its Subsidiaries.

       

      (B)           Transfers Upon Death. Upon the death of the Holder, any Shares then held by the Holder at the time of such death and any Shares acquired after the Holder’s death by the Holder’s
        legal representative shall be subject to the provisions of this Plan, and the Holder’s estate, executors, administrators, personal representatives, heirs, legatees and distributees shall be obligated to convey such Shares to the Company or its
        assigns under the terms contemplated by the Plan and the Award Agreement.

       

      
        13

        
          

      

      (b)          Right of First Refusal. In the event that a Holder desires at any time to sell or otherwise transfer all or any part of his or her Shares (other than shares of Restricted Stock which by their terms
        are not transferrable), the Holder first shall give written notice to the Company of the Holder’s intention to make such transfer. Such notice shall state the number of Shares that the Holder proposes to sell (the “Offered Shares”), the price and
        the terms at which the proposed sale is to be made and the name and address of the proposed transferee. At any time within 30 days after the receipt of such notice by the Company, the Company or its assigns may elect to purchase all or any portion
        of the Offered Shares at the price and on the terms offered by the proposed transferee and specified in the notice. The Company or its assigns shall exercise this right by mailing or delivering written notice to the Holder within the foregoing 30-
        day period. If the Company or its assigns elect to exercise its purchase rights under this Section 9(b), the closing for such purchase shall, in any event, take place within 45 days after the receipt by the Company of the initial notice from the
        Holder. In the event that the Company or its assigns do not elect to exercise such purchase right, or in the event that the Company or its assigns do not pay the full purchase price within such 45-day period, the Holder shall be required to pay a
        transaction processing fee of $10,000 to the Company (unless waived by the Committee) and then may, within 60 days thereafter, sell the Offered Shares to the proposed transferee and at the same price and on the same terms as specified in the
        Holder’s notice. Any Shares not sold to the proposed transferee shall remain subject to the Plan. If the Holder is a party to any stockholders agreements or other agreements with the Company and/or certain other of the Company’s stockholders
        relating to the Shares, (i) the transferring Holder shall comply with the requirements of such stockholders agreements or other agreements relating to any proposed transfer of the Offered Shares, and (ii) any proposed transferee that purchases
        Offered Shares shall enter into such stockholders agreements or other agreements with the Company and/or certain of the Company’s stockholders relating to the Offered Shares on the same terms and in the same capacity as the transferring Holder.

      

      

      
        (c)          Company’s Right of Repurchase.

      

       

      (i)            Right of Repurchase for Unvested Shares Issued Upon the Exercise of an Option. Upon a Termination Event, the Company or its assigns shall have the right and option to repurchase from a
        Holder of Shares acquired upon exercise of a Stock Option which are still subject to a risk of forfeiture as of the Termination Event. Such repurchase rights may be exercised by the Company within the later of (A) six months following the date of
        such Termination Event or (B) seven months after the acquisition of Shares upon exercise of a Stock Option. The repurchase price shall be equal to the lower of the original per share price paid by the Holder, subject to adjustment as provided in
        Section 3(b) of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise its repurchase rights.

       

      (ii)           Right of Repurchase With Respect to Restricted Stock. Upon a Termination Event, the Company or its assigns shall have the right and option to repurchase from a Holder of Shares received pursuant
        to a Restricted Stock Award any Shares that are still subject to a risk of forfeiture as of the Termination Event. Such repurchase right may be exercised by the Company within six months following the date of such Termination Event. The repurchase
        price shall be the lower of the original per share purchase price paid by the Holder, subject to adjustment as provided in Section 3(b) of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise its
        repurchase rights.

       

      

      
        14

        
          

      

      (iii)          Procedure. Any repurchase right of the Company shall be exercised by the Company or its assigns by giving the Holder written notice on or before the last day of the repurchase period of its
        intention to exercise such repurchase right. Upon such notification, the Holder shall promptly surrender to the Company, free and clear of any liens or encumbrances, any certificates representing the Shares being purchased, together with a duly
        executed stock power for the transfer of such Shares to the Company or the Company’s assignee or assignees. Upon the Company’s or its assignee’s receipt of the certificates from the Holder, the Company or its assignee or assignees shall deliver to
        him, her or them a check for the applicable repurchase price; provided, however, that the Company may pay the repurchase price by offsetting and canceling any indebtedness then owed by the Holder to the
        Company.

       

      (d)          Drag Along Right. In the event the holders of a majority of the Company’s equity securities then outstanding (the “Majority Shareholders”) determine to enter into a Sale Event in a bona fide negotiated
        transaction (a “Sale”), with any non-Affiliate of the Company or any majority shareholder (in each case, the “Buyer”), a Holder of Shares, including any Permitted Transferee, shall be obligated to and shall upon the written request of the Majority
        Shareholders: (a) sell, transfer and deliver, or cause to be sold, transferred and delivered, to the Buyer, his or her Shares (including for this purpose all of such Holder’s Shares that presently or as a result of any such transaction may be
        acquired upon the exercise of an Option (following the payment of the exercise price therefor)) on substantially the same terms applicable to the Majority Shareholders (with appropriate adjustments to reflect the conversion of convertible
        securities, the redemption of redeemable securities and the exercise of exercisable securities as well as the relative preferences and priorities of preferred stock); and (b) execute and deliver such instruments of conveyance and transfer and take
        such other action, including voting such Shares in favor of any Sale proposed by the Majority Shareholders and executing any purchase agreements, merger agreements, indemnity agreements, escrow agreements or related documents as the Majority
        Shareholders or the Buyer may reasonably require in order to carry out the terms and provisions of this Section 9(d).

       

      
        (e)          Escrow Arrangement.

      

       

      
        (i)          Escrow. In order to carry out the provisions of this Section 9 of this Plan more effectively, the Company shall hold any Shares issued pursuant to Awards
          granted under the Plan in escrow together with separate stock powers executed by the Holder in blank for transfer. The Company shall not dispose of the Shares except as otherwise provided in this Plan. In the event of any repurchase by the
          Company (or any of its assigns), the Company is hereby authorized by the Holder, as the Holder’s attorney-in-fact, to date and complete the stock powers necessary for the transfer of the Shares being purchased and to transfer such Shares in
          accordance with the terms hereof. At such time as any Shares are no longer subject to the Company’s repurchase and first refusal rights, the Company shall, at the written request of the Holder, deliver to the Holder a certificate representing
          such Shares with the balance of the Shares to be held in escrow pursuant to this Section.

         

        

      

      
        15

        
          

      

      
        (ii)          Remedy. Without limitation of any other provision of this Plan or other rights, in the event that a Holder or any other Person is required to sell a Holder’s Shares pursuant to the provisions of
          Sections 9(b) or (c) hereof and in the further event that he or she refuses or for any reason fails to deliver to the Company or its designated purchaser of such Shares the certificate or certificates evidencing such Shares together with a
          related stock power, the Company or such designated purchaser may deposit the applicable purchase price for such Shares with a bank designated by the Company, or with the Company’s independent public accounting firm, as agent or trustee, or in
          escrow, for such Holder or other Person, to be held by such bank or accounting firm for the benefit of and for delivery to him, her, them or it, and/or, in its discretion, pay such purchase price by offsetting any indebtedness then owed by such
          Holder as provided above. Upon any such deposit and/or offset by the Company or its designated purchaser of such amount and upon notice to the Person who was required to sell the Shares to be sold pursuant to the provisions of Sections 9(b) or
          (c), such Shares shall at such time be deemed to have been sold, assigned, transferred and conveyed to such purchaser, such Holder shall have no further rights thereto (other than the right to withdraw the payment thereof held in escrow, if
          applicable), and the Company shall record such transfer in its stock transfer book or in any appropriate manner.

        

        

        (f)          Lockup Provision. If requested by the Company, a Holder will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
          relating to the Company’s initial public offering (the “IPO”) and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (l80) days), or such other period as may be requested by the
          Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA
          Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
          or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock held immediately prior to the effectiveness of the registration statement for the IPO; or (b) enter into any swap or other
          arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the capital stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of capital stock or
          other securities, in cash or otherwise. The foregoing provisions of this Section 9(f) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holder if all officers,
          directors and holders of more than one percent (1%) of the outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding Preferred Stock) enter into similar agreements. The underwriters in connection with
          the IPO are intended third party beneficiaries of this Section 9(f) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be
          reasonably requested by the underwriters in the IPO that are consistent with this Section 9(f) or that are necessary to give further effect thereto.

        

        

        (g)          Adjustments for Changes in Capital Structure. If, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in
          the Common Stock, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Section 9 shall apply with equal force to additional and/or
          substitute securities, if any, received by Holder in exchange for, or by virtue of his or her ownership of, Shares.

         

        

        
          16

          
            

        

        (h)          Termination. The terms and provisions of Section 9(b) and Section 9(c) (except for the Company’s right to repurchase Shares still subject to a risk of forfeiture upon a

        Termination Event) shall terminate upon the closing of the Company’s Initial Public Offering or upon consummation of any Sale Event, in either case as a result of which Shares are registered under Section 12 of the
          Exchange Act and publicly-traded on any national security exchange.

        

        

        SECTION 10. TAX WITHHOLDING

        

        

        (a)          Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Shares or other amounts received thereunder first becomes includable in the gross income
          of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Committee regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such
          income. The Company and any Subsidiary shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company’s obligation to deliver stock certificates (or evidence
          of book entry) to any grantee is subject to and conditioned on any such tax withholding obligations being satisfied by the grantee.

        

        

        (b)          Payment in Stock. The Company’s minimum required tax withholding obligation may be satisfied, in whole or in part, by the Company withholding from Shares to be issued pursuant to an Award a number
          of Shares having an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the minimum withholding amount due.

         

        SECTION 11.  SECTION 409A AWARDS.

        

        

        To the extent that any Award is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the Award shall be subject to such additional rules and requirements
          as may be specified by the Committee from time to time. In this regard, if any amount under a 409A Award is payable upon a “separation from service” (within the meaning of Section 409A) to a grantee who is considered a “specified employee”
          (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such
          delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. The Company makes no representation or warranty and shall have no liability to any grantee under the Plan
          or any other Person with respect to any penalties or taxes under Section 409A that are, or may be, imposed with respect to any Award.

        

        

        SECTION 12. AMENDMENTS AND TERMINATION

        

        

        The Board may, at any time, amend or discontinue the Plan and the Committee may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no
          such action shall adversely affect rights under any outstanding Award without the consent of the holder of the Award. The Committee may exercise its discretion to reduce the exercise price of outstanding Stock Options or effect repricing through
          cancellation of outstanding Stock Options and by granting such holders new Awards in replacement of the cancelled Stock Options. To the extent determined by the Committee to be required either by the Code to ensure that Incentive Stock Options
          granted under the Plan are qualified under Section 422 of the Code or otherwise, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 12 shall limit the
          Board’s or Committee’s authority to take any action permitted pursuant to Section 3(c). The Board reserves the right to amend the Plan and/or the terms of any outstanding Stock Options to the extent reasonably necessary to comply with the
          requirements of the exemption pursuant to paragraph (f)(4) of Rule 12h-1 of the Exchange Act.

         

        

        
          17

          
            

        

        SECTION 13. STATUS OF PLAN

         

        With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general
          creditor of the Company unless the Committee shall otherwise expressly so determine in connection with any Award.

        

        

        SECTION 14. GENERAL PROVISIONS

        

        

        (a)          No Distribution; Compliance with Legal Requirements. The Committee may require each person acquiring Shares pursuant to an Award to represent to and agree with the Company in writing that such
          person is acquiring the Shares without a view to distribution thereof. No Shares shall be issued pursuant to an Award until all applicable securities law and other legal and stock exchange or similar requirements have been satisfied. The
          Committee may require the placing of such stop-orders and restrictive legends on certificates for Stock and Awards as it deems appropriate.

         

        (b)          Delivery of Stock Certificates. Stock certificates to grantees under the Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed
          such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company; provided that stock certificates to be held in escrow pursuant to Section 9 of the Plan shall be deemed delivered
          when the Company shall have recorded the issuance in its records. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have given to the grantee by electronic mail (with
          proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic “book entry” records).

         

        (c)          No Employment Rights. The adoption of the Plan and the grant of Awards do not confer upon any Person any right to continued employment or Service
          Relationship with the Company or any Subsidiary.

         

        (d)          Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading policy-related restrictions, terms and conditions as may be
          established by the Committee, or in accordance with policies set by the Committee, from time to time.

         

        

        
          18

          
            

        

        (e)          Designation of Beneficiary. Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award on or after the grantee’s death or receive
          any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Committee and shall not be effective until received by the Committee. If no beneficiary has been
          designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate.

        

        

        (f)          Legend. Any certificate(s) representing the Shares shall carry substantially the following legend (and with respect to uncertificated Stock, the book entries evidencing such shares shall contain
          the following notation):

        

        

        The transferability of this certificate and the shares of stock represented hereby are subject to the restrictions, terms and conditions (including repurchase and restrictions against transfers)
          contained in the Disc Medicine, Inc. 2017 Stock Option and Grant Plan and any agreements entered into thereunder by and between the company and the holder of this certificate (a copy of which is available at the offices of the company for
          examination).

        

        

        (g)          Information to Holders of Options. In the event the Company is relying on the exemption from the registration requirements of Section 12(g) of the Exchange Act contained in paragraph (f)(1) of
          Rule 12h-1 of the Exchange Act, the Company shall provide the information described in Rule 701(e)(3), (4) and (5) of the Securities Act to all holders of Options in accordance with the requirements thereunder. The foregoing notwithstanding, the
          Company shall not be required to provide such information unless the optionholder has agreed in writing, on a form prescribed by the Company, to keep such information confidential.

         

        SECTION 15. EFFECTIVE DATE OF PLAN

         

        The Plan shall become effective upon adoption by the Board and shall be approved by stockholders in accordance with applicable state law and the Company’s articles of incorporation and bylaws within 12 months
          thereafter. If the stockholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any Awards granted or sold under the Plan shall be rescinded and no additional grants or sales shall thereafter be made
          under the Plan. Subject to such approval by stockholders and to the requirement that no Shares may be issued hereunder prior to such approval, Stock Options and other Awards may be granted hereunder on and after adoption of the Plan by the Board.
          No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the date the Plan is adopted by the Board or the date the Plan is approved by the Company’s stockholders, whichever is earlier.

         

        SECTION 16. GOVERNING LAW

         

        This Plan, all Awards and any controversy arising out of or relating to this Plan and all Awards shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to
          matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the
          application of any law other than the law of the Commonwealth of Massachusetts.

        

        

        	
                DATE ADOPTED BY THE BOARD OF DIRECTORS:

              	
                November 15, 2017

              
	 	 
	
                DATE APPROVED BY THE STOCKHOLDERS:

              	
                November 27, 2017

              

        

        

        
          19

          
            

        

        AMENDMENT NO. 1 

        TO THE

         DISC MEDICINE, INC.

         2017 STOCK OPTION AND GRANT PLAN

        

        

        The Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”) is hereby amended as follows:

        

        

        
          1.           Section 3(a) of the Plan is hereby amended and restated in its entirety as follows:

        

        

        

        “(a) Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 937,136 Shares, subject to adjustment as provided in
          Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and
          Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may
          be issued up to such maximum number pursuant to any type or types of Award, and no more than 9,371,360 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued
          Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 9,371,360 Shares shall be granted to any one individual in any calendar year
          period.”

        

        

        
          2.           All other terms and conditions of the Plan shall remain in full force and effect.

        

        

        

        	
                ADOPTED BY BOARD OF DIRECTORS:

              	
                April 30, 2019

              
	 	 
	
                ADOPTED BY STOCKHOLDERS:

              	
                April 30, 2019

              

         

        

        
          20

          
            

        

        AMENDMENT NO. 2 

        TO THE

        DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

        

        

        The Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”) is hereby amended as follows:

         

        
          1.           Section 3(a) of the Plan is hereby amended and restated in its entirety as follows:

        

         

        “(a) Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 7,562,358 Shares, subject to adjustment as provided in
          Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and
          Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may
          be issued up to such maximum number pursuant to any type or types of Award, and no more than 75,623,580 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued
          Shares or Shares reacquired by the Company.   Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 7,562,358 Shares shall be granted to any one individual in any calendar year
          period.”

         

        
          2.           All other terms and conditions of the Plan shall remain in full force and effect.

        

        

        

        	
                ADOPTED BY BOARD OF DIRECTORS:

              	
                September 12, 2019

              
	 	 
	
                ADOPTED BY STOCKHOLDERS:

              	
                September 12, 2019

              

         

        
          21

          
            

        

        AMENDMENT NO. 3 

        TO THE

        DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

        

        

        The Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”) is hereby amended as follows:

         

        
          1.           Section 3(a) of the Plan is hereby amended and restated in its entirety as follows:

        

         

        “(a) Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 9,724,496 Shares, subject to adjustment as provided in
          Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and
          Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may
          be issued up to such maximum number pursuant to any type or types of Award, and no more than 50,000,000 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued
          Shares or Shares reacquired by the Company.   Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 50,000,000 Shares shall be granted to any one individual in any calendar year
          period.”

         

        
          2.           All other terms and conditions of the Plan shall remain in full force and effect.

        

        

        

        	
                ADOPTED BY BOARD OF DIRECTORS:

              	
                October 23, 2020

              
	 	 
	
                ADOPTED BY STOCKHOLDERS:

              	
                October 26, 2020

              

         

        
          22

          
            

        

        AMENDMENT 

        NO. 4 TO THE

        DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

        

        

        The Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”) is hereby amended as follows:

        

        

        
          1.           Section 3(a) of the Plan is hereby amended and restated in its entirety as follows:

        

        

        

         “(a) Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 16,216,325 Shares, subject to adjustment as provided in Section
          3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares
          that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be
          issued up to such maximum number pursuant to any type or types of Award, and no more than 50,000,000 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares
          or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 50,000,000 Shares shall be granted to any one individual in any calendar year period.”

        

        

        
          2.           All other terms and conditions of the Plan shall remain in full force and effect.

        

        

        

        ADOPTED BY BOARD OF DIRECTORS: August 23, 2021

         

        

        ADOPTED BY STOCKHOLDERS:  August 23, 2021

        

        

        
          23

          
            

        

        AMENDMENT NO. 5

        TO THE

        DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

        

        

        The Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”) is hereby amended as follows:

        

        

        
          1.           Section 3(a) of the Plan is hereby amended and restated in its entirety as follows:

        

         

        “(a) Stock Issuable.  The maximum number of Shares reserved and available for issuance under the Plan shall be 17,503,334 Shares, subject to adjustment as provided in Section 3(b). For
          purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are
          withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to
          such maximum number pursuant to any type or types of Award, and no more than 50,000,000 Shares may be issued pursuant to Incentive Stock Options.  The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares
          reacquired by the Company.  Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 50,000,000 Shares shall be granted to any one individual in any calendar year period.”

         

        
          2.           All other terms and conditions of the Plan shall remain in full force and effect.

        

         

        	
                ADOPTED BY BOARD OF DIRECTORS:

              	
                July 21, 2022

              
	 	 
	
                ADOPTED BY STOCKHOLDERS:

              	
                July 23, 2022

              

        

        

        
          24

          
            

        

        INCENTIVE STOCK OPTION GRANT NOTICE

        UNDER THE DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

         

        

        Pursuant to the Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”), Disc Medicine, Inc. a Delaware corporation (together with any successor, the “Company”), has
          granted to the individual named below, an option (the “Stock Option”) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part of the number of shares of Common Stock, par value $0.0001 per
          share (“Common Stock”), of the Company indicated below (the “Shares”), at the Option Exercise Price per share, subject to the terms and conditions set forth in this Incentive Stock Option Grant Notice (the “Grant Notice”), the attached Incentive
          Stock Option Agreement (the “Agreement”) and the Plan.  This Stock Option is intended to qualify as an “incentive stock option” as defined in Section 422(b) of the Internal Revenue Code of 1986, as amended from time to time (the “Code”).  To the
          extent that any portion of the Stock Option does not so qualify, it shall be deemed a non‐qualified stock option.

        	
                Name of Optionee:

              	
                __________________ (the “Optionee”)

              
	
                No. of Shares:

              	
                __________ Shares of Common Stock

              
	
                Grant Date:

              	
                __________________

              
	
                Vesting Commencement Date:

              	
                __________________ (the “Vesting Commencement Date”)

              
	
                Expiration Date:

              	
                __________________ (the “Expiration Date”)

              
	
                Option Exercise Price/Share:

              	
                $_________________ (the “Option Exercise Price”)

              
	
                Vesting Schedule:

              	
                [25] percent of the Shares shall vest and become exercisable on the first anniversary of the Vesting Commencement Date; provided that the Optionee continues to have a Service Relationship with the Company at such time.   Thereafter,
                  the remaining [75] percent of the Shares shall vest and become exercisable in [36] equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship
                  with the Company on each vesting date.  Notwithstanding anything in the Agreement to the contrary, in the case of a Sale Event, this Stock Option and the Shares shall be treated as provided in Section 3(c) of the Plan[ provided; however INSERT ANY ACCELERATED VESTING PROVISION HERE].

              

         

        

        Attachments:  Incentive Stock Option Agreement, 2017 Stock Option and Grant Plan

         

        
          25

          
            

        

        INCENTIVE STOCK OPTION AGREEMENT

        UNDER THE DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

         

        

        All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.

         

        

        1.           Vesting, Exercisability and Termination.

         

        (a)            No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable.

         

        (b)            Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule hereunder, this Stock Option shall be vested and exercisable on
          the respective dates indicated below:

         

        (i)           This Stock Option shall initially be unvested and unexercisable.

         

        (ii)          This Stock Option shall vest and become exercisable in accordance with the Vesting Schedule set forth in the Grant Notice.

         

        (c)            Termination.  Except as may otherwise be provided by the Committee, if the Optionee’s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject
          to earlier termination as set forth below (and if not exercised within such period, shall thereafter terminate subject, in each case, to Section 3(c) of the Plan):

         

        (i)           Termination Due to Death or Disability.  If the Optionee’s Service Relationship terminates by reason of such Optionee’s death or Disability, this Stock Option may be
          exercised, to the extent exercisable on the date of such termination, by the Optionee, the Optionee’s legal representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier.

         

        (ii)          Other Termination.  If the Optionee’s Service Relationship terminates for any reason other than death or Disability, and unless otherwise determined by the Committee, this
          Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier; provided however, if the Optionee’s Service
          Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination.

         

        For purposes hereof, the Committee’s determination of the reason for termination of the Optionee’s Service Relationship shall be conclusive and binding on the Optionee and his or her representatives or legatees.  Any
          portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall terminate immediately and be null and void.

         

        

        (d)           It is understood and intended that this Stock Option is intended to qualify as an “incentive stock option” as defined in Section 422 of the Code to the extent permitted under applicable law. 
          Accordingly, the Optionee understands that in order to obtain the benefits of an incentive stock option under Section 422 of the Code, no sale or other disposition may be made of Shares for which incentive stock option treatment is desired within
          the one‐year period beginning on the day after the day of the transfer of such Shares to him or her, nor within the two‐year period beginning on the day after Grant Date of this Stock Option and further that this Stock Option must be exercised
          within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an incentive stock option.  If the Optionee disposes (whether by sale, gift, transfer or otherwise) of any such
          Shares within either of these periods, he or she will notify the Company within 30 days after such disposition.  The Optionee also agrees to provide the Company with any information concerning any such dispositions required by the Company for tax
          purposes.  Further, to the extent this Stock Option and any other incentive stock options of the Optionee having an aggregate Fair Market Value in excess of $100,000 (determined as of the Grant Date) first become exercisable in any year, such
          options will not qualify as incentive stock options.

         

        
          26

          
            

        

        2.           Exercise of Stock Option.

         

        (a)          The Optionee may exercise this Stock Option only in the following manner:  Prior to the Expiration Date, the Optionee may deliver a Stock Option exercise notice (an “Exercise Notice”) in the form of Appendix

            A hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable.  Such notice shall specify the number of Shares to be purchased.  Payment of the purchase price may
          be made by one or more of the methods described in Section 5 of the Plan, subject to the limitations contained in such Section of the Plan, including the requirement that the Committee specifically approve in advance certain payment methods.

         

        (b)          Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date.

         

        3.           Incorporation of Plan.  Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan.

         

        4.            Transferability of Stock Option.  This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner other than by will or by the laws of descent and
          distribution.  The Stock Option may be exercised during the Optionee’s lifetime only by the Optionee (or by the Optionee’s guardian or personal representative in the event of the Optionee’s incapacity).  The Optionee may elect to designate a
          beneficiary by providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation or change with the Company; such beneficiary may exercise the
          Optionee’s Stock Option in the event of the Optionee’s death to the extent provided herein.  If the Optionee does not designate a beneficiary, or if the designated beneficiary predeceases the Optionee, the legal representative of the Optionee may
          exercise this Stock Option to the extent provided herein in the event of the Optionee’s death.

         

        5.           Restrictions on Transfer of Shares.  The Shares acquired upon exercise of the Stock Option shall be subject to certain transfer restrictions and other limitations including, without limitation,
          the provisions contained in Section 9 of the Plan.

         

        6.            Miscellaneous Provisions.

         

        (a)            Equitable Relief.  The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief, including specific
          performance and injunctive relief, may be used to enforce the provisions of this Agreement.

         

        
          27

          
            

        

        (b)            Adjustments for Changes in Capital Structure.  If, as a result of any reorganization, recapitalization, reincorporation, reclassification, stock dividend, stock split, reverse stock split or
          other similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Agreement shall apply
          with equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares acquired pursuant thereto.

         

        (c)            Change and Modifications.  This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective.  This Agreement may be changed, modified
          or terminated only by an agreement in writing signed by the Company and the Optionee.

         

        (d)            Governing Law.  This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all
          other matters shall be governed by and construed in accordance with the internal laws of Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the State
          of Commonwealth of Massachusetts.

         

        (e)            Headings.  The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the
          interpretation of this Agreement.

         

        (f)            Saving Clause.  If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any
          other provision hereof.

         

        (g)            Notices.  All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if
          mailed by first class registered or certified mail, postage prepaid.  Notices to the Company or the Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by
          such party in writing to the other.

         

        (h)            Benefit and Binding Effect.  This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal representatives.  The
          Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.

         

        (i)            Counterparts.  For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
          which shall constitute one and the same document.

         

        
          28

          
            

        

        (j)            Integration.  This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties
          concerning such subject matter, including but not limited to, any written or oral offer letter or consulting or service agreement between the parties that provides for the issuance of equity in the Company.

         

        7.           Dispute Resolution.

         

        (a)            Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach, termination or validity of the Plan, this Stock Option or this
          Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the “J.A.M.S. Rules”).  The arbitration shall be governed by the United
          States Arbitration Act, 9 U.S.C. Sections 1 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.  The place of arbitration shall be Boston, Massachusetts.

         

        (b)           The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.  In connection with the arbitration proceeding, the arbitrator shall
          have the power to order the production of documents by each party and any third-party witnesses.  In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions
          upon good cause shown by the moving party.  However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.  In connection with any arbitration, each party to the arbitration
          shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the arbitration or considered
          or used by a party’s witness or expert.  The arbitrator’s decision and award shall be made and delivered within six months of the selection of the arbitrator.  The arbitrator’s decision shall set forth a reasoned basis for any award of damages or
          finding of liability.  The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such
          damages.

         

        (c)           The Company, the Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such party will participate in the
          arbitration in good faith.  This Section 7 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior
          arbitration for the limited purpose of avoiding immediate and irreparable harm.

         

        (d)           Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding,
          (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is
          exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or
          the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such
          court.  Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.  Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by
          mail is made for the express benefit of each other Party.  Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner
          provided by or pursuant to the laws of such other jurisdiction.

         

        [SIGNATURE PAGE FOLLOWS]

         

        

        
          29

          
            

        

        The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned as of the date first above written.

         

        

        	 	
                DISC MEDICINE, INC.

              
	 	 
	 	
                By:

              	 
	 	 	
                Name:

              	 
	 	 	
                Title:

              	 
	 	 	 	 
	 	
                Address:

              	 
	 	 	 
	 	 	  
	 	 	  
	 	 	  

         

        

        The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section 9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement.  This Agreement
          is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 7 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date
          first above written.

         

        	 	
                OPTIONEE:

              
	 	 
	 	
                Name:

              
	 	 
	 	
                Address:

              
	 	 
	 	 
	 	 
	 	 

         

        

        
          30

          
            

        

        
          	
                  
                    [SPOUSE’S CONSENT1

                    I acknowledge that I have read the

                    foregoing Incentive Stock Option Agreement

                    and understand the contents thereof.

                  

                  ]

                

          

          

        

        1 A spouse’s consent is recommended only if the Optionee’s state of residence is one of the following community property states: 
          Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and Wisconsin.

         

        
          31

          
            

        

        	 	
                DESIGNATED BENEFICIARY:

              
	 	 
	 	 
	 	
                Beneficiary’s Address:

              
	 	 
	 	 
	 	 
	 	 

         

        

        
          32

          
            

        

        Appendix A

         

        STOCK OPTION EXERCISE NOTICE

         

        DISC MEDICINE, INC.

        Attention: [____________________]

        ____________________________

        ____________________________

         

        Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Disc Medicine, Inc.  (the “Company”) dated __________ (the “Agreement”) under the Disc Medicine, Inc. 2017 Stock Option and Grant Plan, I, [Insert Name] ________________, hereby [Circle One] partially/fully exercise such option by including herein payment in the amount
          of $______ representing Disc Medicine, Inc. the purchase price for [Fill in number of Shares] _______ Shares.  I have chosen the following form(s) of payment:

        [ ]          1.          Cash

        [ ]          2.          Certified or bank check payable to Disc Medicine, Inc.

        
          
            	

                  	[ ]          	3.          	Other (as referenced in the Agreement and described in the Plan (please describe)) ________________________________.

          

        

         

        In connection with my exercise of the option as set forth above, I hereby represent and warrant to the Company as follows:

         

        

        (i)            I am purchasing the Shares for my own account for investment only, and not for resale or with a view to the distribution thereof.

         

        (ii)          I have had such an opportunity as I have deemed adequate to obtain from the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in
          the Company and have consulted with my own advisers with respect to my investment in the Company.

         

        (iii)          I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment
          decision with respect to such purchase.

         

        (iv)          I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time.

         

        (v)          I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares are being issued and sold in reliance on the exemption provided
          in Rule 701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective registration statement under the Securities Act of 1933 and under any
          applicable state securities or “blue sky” laws (or exemptions from the registration requirement thereof).  I further acknowledge that certificates representing Shares will bear restrictive legends reflecting the foregoing and/or that book entries
          for uncertificated Shares will include similar restrictive notations.

         

        
          33

          
            

        

        (vi)          I have read and understand the Plan and acknowledge and agree that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer
          restrictions set forth in Section 9 of the Plan.

         

        (vii)         I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to Section 9(b) of the Plan.

         

        (viii)        I understand and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section 9(c) of the Plan.

         

        (ix)          I understand and agree that I may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as
          described in Section 9(f) of the Plan.

         

        	 	
                Sincerely yours,

              
	 	 
	 	 
	 	
                Name:

              	 
	 	 	 
	 	
                Address:

              	 
	 	 
	 	 
	 	 
	 	 
	 	 	 
	 	
                Date:

              	 

        

        

        
          34

          
            

        

        NON-QUALIFIED STOCK OPTION GRANT NOTICE

        UNDER THE DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

         

        

        Pursuant to the Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”), Disc Medicine, Inc. a Delaware corporation (together with any successor, the “Company”), has granted to the individual named below,
          an option (the “Stock Option”) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part of the number of shares of Common Stock, par value $0.0001 per share (“Common Stock”), of the Company
          indicated below (the “Shares”), at the Option Exercise Price per share, subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the “Grant Notice”), the attached Non-Qualified Stock Option Agreement (the
          “Agreement”) and the Plan.  This Stock Option is not intended to qualify as an “incentive stock option” as defined in Section 422(b) of the Internal Revenue Code of 1986, as amended from time to time (the “Code”).

        	
                Name of Optionee:

              	
                __________________ (the “Optionee”)

              
	
                No. of Shares:

              	
                __________ Shares of Common Stock

              
	
                Grant Date:

              	
                __________________

              
	
                Vesting Commencement Date:

              	
                __________________ (the “Vesting Commencement Date”)

              
	
                Expiration Date:

              	
                __________________ (the “Expiration Date”)

              
	
                Option Exercise Price/Share:

              	
                $_________________ (the “Option Exercise Price”)

              
	
                Vesting Schedule:

              	
                [25] percent of the Shares shall vest and become exercisable on the first anniversary of the Vesting Commencement Date; provided that the Optionee continues to have a Service Relationship with the Company at such time.   Thereafter,
                  the remaining [75] percent of the Shares shall vest and become exercisable in [36] equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship
                  with the Company on each vesting date.  Notwithstanding anything in the Agreement to the contrary, in the case of a Sale Event, this Stock Option and the Shares shall be treated as provided in Section 3(c) of the Plan[ provided; however INSERT ANY ACCELERATED VESTING PROVISION HERE].

              

         

        

        Attachments:  Non-Qualified Stock Option Agreement, 2017 Stock Option and Grant Plan

         

        
          35

          
            

        

        NON-QUALIFIED STOCK OPTION AGREEMENT

        UNDER THE DISC MEDICINE, INC.

        2017 STOCK OPTION AND GRANT PLAN

         

        

        All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.

         

        

        1.          Vesting, Exercisability and Termination.

         

        (a)           No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable.

         

        (b)           Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule hereunder, this Stock Option shall be vested and exercisable on the
          respective dates indicated below:

         

        (i)           This Stock Option shall initially be unvested and unexercisable.

         

        (ii)          This Stock Option shall vest and become exercisable in accordance with the Vesting Schedule set forth in the Grant Notice.

         

        (c)            Termination.  Except as may otherwise be provided by the Committee, if the Optionee’s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject
          to earlier termination as set forth below (and if not exercised within such period, shall thereafter terminate subject, in each case, to Section 3(c) of the Plan):

         

        (i)          Termination Due to Death or Disability.  If the Optionee’s Service Relationship terminates by reason of such Optionee’s death or Disability, this Stock Option may be exercised,
          to the extent exercisable on the date of such termination, by the Optionee, the Optionee’s legal representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier.

         

        (ii)          Other Termination.  If the Optionee’s Service Relationship terminates for any reason other than death or Disability, and unless otherwise determined by the Committee, this
          Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier; provided however, if the Optionee’s Service
          Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination.

         

        For purposes hereof, the Committee’s determination of the reason for termination of the Optionee’s Service Relationship shall be conclusive and binding on the Optionee and his or her representatives or legatees and
          any Permitted Transferee.  Any portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall terminate immediately and be null and void.

         

        

        2.          Exercise of Stock Option.

         

        (a)            The Optionee may exercise this Stock Option only in the following manner:  Prior to the Expiration Date, the Optionee may deliver a Stock Option exercise notice (an “Exercise Notice”) in the form of Appendix

            A hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable.  Such notice shall specify the number of Shares to be purchased.  Payment of the purchase price may
          be made by one or more of the methods described in Section 5 of the Plan, subject to the limitations contained in such Section of the Plan, including the requirement that the Committee specifically approve in advance certain payment methods.

         

        
          36

          
            

        

        (b)          Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date.

         

        3.           Incorporation of Plan.  Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan.

         

        4.          Transferability of Stock Option.  This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner other than by will or by the laws of descent and distribution. 
          The Stock Option may be exercised during the Optionee’s lifetime only by the Optionee (or by the Optionee’s guardian or personal representative in the event of the Optionee’s incapacity).  The Optionee may elect to designate a beneficiary by
          providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation or change with the Company; such beneficiary may exercise the Optionee’s Stock
          Option in the event of the Optionee’s death to the extent provided herein.  If the Optionee does not designate a beneficiary, or if the designated beneficiary predeceases the Optionee, the legal representative of the Optionee may exercise this
          Stock Option to the extent provided herein in the event of the Optionee’s death.

         

        5.          Restrictions on Transfer of Shares.  The Shares acquired upon exercise of the Stock Option shall be subject to certain transfer restrictions and other limitations including, without limitation, the
          provisions contained in Section 9 of the Plan.

         

        6.          Miscellaneous Provisions.

         

        (a)          Equitable Relief.  The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief, including specific performance
          and injunctive relief, may be used to enforce the provisions of this Agreement.

         

        (b)          Adjustments for Changes in Capital Structure.  If, as a result of any reorganization, recapitalization, reincorporation, reclassification, stock dividend, stock split, reverse stock split or other
          similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Agreement shall apply with
          equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares acquired pursuant thereto.

         

        (c)          Change and Modifications.  This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective.  This Agreement may be changed, modified or
          terminated only by an agreement in writing signed by the Company and the Optionee.

         

        
          37

          
            

        

        (d)           Governing Law.  This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all
          other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the
          Commonwealth of Massachusetts.

         

        (e)           Headings.  The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation
          of this Agreement.

         

        (f)           Saving Clause.  If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any other
          provision hereof.

         

        (g)           Notices.  All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if
          mailed by first class registered or certified mail, postage prepaid.  Notices to the Company or the Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by
          such party in writing to the other.

         

        (h)           Benefit and Binding Effect.  This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal representatives.  The
          Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.

         

        (i)            Counterparts.  For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
          which shall constitute one and the same document.

         

        (j)           Integration.  This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties
          concerning such subject matter, including but not limited to, any written or oral offer letter or consulting or service agreement between the parties that provides for the issuance of equity in the Company.

         

        7.           Dispute Resolution.

          

        

        (a)           Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach, termination or validity of the Plan, this Stock Option or this
          Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the “J.A.M.S. Rules”).  The arbitration shall be governed by the United
          States Arbitration Act, 9 U.S.C. Sections 1-16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.  The place of arbitration shall be Boston, Massachusetts.

         

        
          38

          
            

        

        (b)          The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.  In connection with the arbitration proceeding, the arbitrator shall have
          the power to order the production of documents by each party and any third-party witnesses.  In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon
          good cause shown by the moving party.  However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.  In connection with any arbitration, each party to the arbitration shall
          provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the arbitration or considered or
          used by a party’s witness or expert.  The arbitrator’s decision and award shall be made and delivered within six months of the selection of the arbitrator.  The arbitrator’s decision shall set forth a reasoned basis for any award of damages or
          finding of liability.  The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such
          damages.

         

        (c)          The Company, the Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such party will participate in the
          arbitration in good faith.  This Section 7 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior
          arbitration for the limited purpose of avoiding immediate and irreparable harm.

         

        (d)          Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (ii)
          hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt
          or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the
          subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court. 
          Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.  Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is
          made for the express benefit of each other Party.  Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or
          pursuant to the laws of such other jurisdiction.

         

        [SIGNATURE PAGE FOLLOWS]

         

        

        
          39

          
            

        

        The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned as of the date first above written.

         

        

        	 	
                DISC MEDICINE, INC.

              
	 	 
	 	
                By:

              	 	 
	 	 	
                Name:

              	 
	 	 	
                Title:

              	 
	 	 	 	 
	 	
                Address:

              
	 	 
	 	 
	 	 
	 	 

         

        

        The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section 9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement.  This Agreement
          is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 7 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date
          first above written.

         

        	 	
                OPTIONEE:

              
	 	 
	 	 
	 	
                Name:

              	 
	 	 	 
	 	
                Address:

              	 
	 	 
	 	 
	 	 
	 	 

        

        

        
          40

          
            

        

        	
                
                  [SPOUSE’S CONSENT2

                  I acknowledge that I have read the

                  foregoing Non-Qualified Stock Option Agreement

                  and understand the contents thereof.

                

                 ]

              

        

        

         

          

        2 A spouse’s consent is recommended only if the Optionee’s state of residence is one of the following community property states: 
          Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and Wisconsin.

         

        
          41

          
            

        

        	 	
                DESIGNATED BENEFICIARY:

              
	 	 
	 	 
	 	 
	 	
                Beneficiary’s Address:

              
	 	 
	 	 
	 	 
	 	 

         

        

        
          42

          
            

        

        Appendix A

         

        STOCK OPTION EXERCISE NOTICE

         

        DISC MEDICINE, INC.

        Attention: [____________________]

        ____________________________

        ____________________________

         

        Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Disc Medicine, Inc. (the “Company”) dated __________ (the “Agreement”) under the Disc Medicine, Inc.2017 Stock Option and Grant Plan, I, [Insert Name] ________________, hereby [Circle One] partially/fully exercise such option by including herein payment in the amount of $______ representing the purchase price for
          [Fill in number of Shares] _______ Shares.  I have chosen the following form(s) of payment:

        [ ]          1.          Cash

        [ ]          2.          Certified or bank check payable to Disc Medicine, Inc.

        
          
            	

                  	[ ]          	3.          	Other (as referenced in the Agreement and described in the Plan (please describe)) _____________________________________________________.

          

        

         

        In connection with my exercise of the option as set forth above, I hereby represent and warrant to the Company as follows:

         

        

        (i)           I am purchasing the Shares for my own account for investment only, and not for resale or with a view to the distribution thereof.

         

        (ii)          I have had such an opportunity as I have deemed adequate to obtain from the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in
          the Company and have consulted with my own advisers with respect to my investment in the Company.

         

        (iii)          I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment
          decision with respect to such purchase.

         

        (iv)          I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time.

         

        (v)          I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares are being issued and sold in reliance on the exemption provided
          in Rule 701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective registration statement under the Securities Act of 1933 and under any
          applicable state securities or “blue sky” laws (or exemptions from the registration requirement thereof).  I further acknowledge that certificates representing Shares will bear restrictive legends reflecting the foregoing and/or that book entries
          for uncertificated Shares will include similar restrictive notations.

         

        
          43

          
            

        

        (vi)          I have read and understand the Plan and acknowledge and agree that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer
          restrictions set forth in Section 9 of the Plan.

         

        (vii)        I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to Section 9(b) of the Plan.

         

        (viii)       I understand and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section 9(c) of the Plan.

         

        (ix)          I understand and agree that I may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as
          described in Section 9(f) of the Plan.

         

        	 	
                Sincerely yours,

              
	 	 
	 	 
	 	
                Name:

              	 
	 	 	 
	 	
                Address:

              	 
	 	 
	 	 
	 	 
	 	 
	 	 	 
	 	
                Date:

              	 

        

        

        
          44

          
            

        

        Restricted Stock AWARD NOTICE

        under the Disc Medicine, Inc.

        2017 Stock Option and Grant Plan

         

        

        Pursuant to the Disc Medicine, Inc. 2017 Stock Option and Grant Plan (the “Plan”), Disc Medicine, Inc., a Delaware corporation (together with any successor, the “Company”), hereby grants, sells and issues to the
          individual named below, the Shares at the Per Share Purchase Price, subject to the terms and conditions set forth in this Restricted Stock Award Notice (the “Award Notice”), the attached Restricted Stock Agreement (the “Agreement”) and the Plan. 
          The Grantee agrees to the provisions set forth herein and acknowledges that each such provision is a material condition of the Company’s agreement to issue and sell the Shares to him or her.  The Company hereby acknowledges receipt of $[_______] in full payment for the Shares.  All references to share prices and amounts herein shall be equitably adjusted to reflect stock splits, stock dividends, recapitalizations, mergers, reorganizations and
          similar changes affecting the capital stock of the Company, and any shares of capital stock of the Company received on or in respect of Shares in connection with any such event (including any shares of capital stock or any right, option or
          warrant to receive the same or any security convertible into or exchangeable for any such shares or received upon conversion of any such shares) shall be subject to this Agreement on the same basis and extent at the relevant time as the Shares in
          respect of which they were issued, and shall be deemed Shares as if and to the same extent they were issued at the date hereof.

        	
                Name of Grantee:

              	
                _________________ (the “Grantee”)

              
	
                No. of Shares:

              	
                _________ Shares of Common Stock (the “Shares”)

              
	
                Grant Date:

              	
                ____________ __, ____

              
	
                Date of Purchase of Shares:

              	
                ____________ __, ____

              
	
                Vesting Commencement Date:

              	
                ____________ __, ____ (the “Vesting Commencement Date”)

              
	
                Per Share Purchase Price:

              	
                $________ (the “Per Share Purchase Price”)

              
	
                Vesting Schedule:

              	
                [25] percent of the Shares shall vest on the [first] anniversary of the Vesting Commencement Date; provided that the Grantee continues to have a Service Relationship with the Company at such time.  Thereafter, the remaining [75]
                  percent of the Shares shall vest in [36] equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Grantee continues to have a Service Relationship with the Company at such time. 
                  Notwithstanding anything in the Agreement to the contrary in the case of a Sale Event, the Shares of Restricted Stock shall be treated as provided in Section 3(c) of the Plan [provided; however INSERT ANY ACCELERATED VESTING PROVISION HERE].

              

        

          Attachments:  Restricted Stock Agreement, 2017 Stock Option and Grant Plan

        

        
          

        

        

        
          45

          
            

        

        Restricted Stock Agreement

        under the Disc Medicine, Inc.

        2017 Stock Option and Grant Plan

         

        

        All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Award Notice and the Plan.

         

        

        1.          Purchase and Sale of Shares; Vesting; Investment Representations.

         

        (a)           Purchase and Sale.  The Company hereby sells to the Grantee, and the Grantee hereby purchases from the Company, the number of Shares set forth in the Award Notice for the Per Share Purchase
          Price.

         

        (b)           Vesting.  Initially, all of the Shares are non-transferable and subject to a substantial risk of forfeiture and are Shares of Restricted Stock.  The risk of forfeiture shall lapse with respect to the Shares on the respective dates indicated on the Vesting Schedule set forth in the Award Notice.

         

        (c)           Investment Representations.  In connection with the purchase and sale of the Shares contemplated by Section 1(a) above, the Grantee hereby represents and warrants to the Company as follows:

         

        (i)            The Grantee is purchasing the Shares for the Grantee’s own account for investment only, and not for resale or with a view to the distribution thereof.

         

        (ii)          The Grantee has had such an opportunity as he or she has deemed adequate to obtain from the Company such information as is necessary to permit him or her to evaluate the merits and
          risks of the Grantee’s investment in the Company and has consulted with the Grantee’s own advisers with respect to the Grantee’s investment in the Company.

         

        (iii)          The Grantee has sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed
          investment decision with respect to such purchase.

         

        (iv)          The Grantee can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period.

         

        (v)          The Grantee understands that the Shares are not registered under the Act (it being understood that the Shares are being issued and sold in reliance on the exemption provided in Rule
          701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective registration statement under the Act and under any applicable state securities or
          “blue sky” laws (or exemptions from the registration requirements thereof).  The Grantee further acknowledges that certificates representing the Shares will bear restrictive legends reflecting the foregoing and/or that book entries for
          uncertificated Shares will include similar restrictive notations.

         

        
          46

          
            

        

        (vi)          The Grantee has read and understands the Plan and acknowledges and agrees that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the
          transfer restrictions set forth in Section 9 of the Plan.

         

        (vii)         The Grantee understands and agrees that the Company has a right of first refusal with respect to the Shares pursuant to Section 9(b) of the Plan.

         

        (viii)        The Grantee understands and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section 9(c) of the Plan.

         

        (ix)          The Grantee understands and agrees that the Grantee may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering
          by the Company as described in Section 9(f) of the Plan.

         

        2.           Repurchase Right.  Upon a Termination Event, the Company shall have the right to repurchase Shares of Restricted Stock that are unvested as of the date of such Termination Event as set forth in
          Section 9(c) of the Plan.

         

        3.           Restrictions on Transfer of Shares.  The Shares (whether or not vested) shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions
          contained in Section 9 of the Plan

         

        4.           Incorporation of Plan.  Notwithstanding anything herein to the contrary, this Restricted Stock Award shall be subject to and governed by all the terms and conditions of the Plan.

         

        5.           Miscellaneous Provisions.

         

        (a)           Record Owner; Dividends.  The Grantee and any Permitted Transferees, during the duration of this Agreement, shall be considered the record owners of and shall be entitled to vote the Shares if
          and to the extent the Shares are entitled to voting rights.  The Grantee and any Permitted Transferees shall be entitled to receive all dividends and any other distributions declared on the Shares; provided, however, that the
          Company is under no duty to declare any such dividends or to make any such distribution.

         

        (b)           Section 83(b) Election.  The Grantee shall consult with the Grantee’s tax advisor to determine whether it would be appropriate for the Grantee to make an election under Section 83(b) of the Code
          with respect to this Award.  Any such election must be filed with the Internal Revenue Service within 30 days of the date of this Award.  If the Grantee makes an election under Section 83(b) of the Code, the Grantee shall give prompt notice to
          the Company (and provide a copy of such election to the Company).

         

        (c)           Equitable Relief.  The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief, including specific
          performance and injunctive relief, may be used to enforce the provisions of this Agreement.

         

        
          47

          
            

        

        (d)          Change and Modifications.  This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective. This Agreement may be changed, modified or
          terminated only by an agreement in writing signed by the Company and the Grantee.

         

        (e)          Governing Law.  This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all
          other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the
          Commonwealth of Massachusetts.

         

        (f)           Headings.  The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation
          of this Agreement.

         

        (g)           Saving Clause.  If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any other
          provision hereof.

         

        (h)           Notices.  All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if
          mailed by first class registered or certified mail, postage prepaid.  Notices to the Company or the Grantee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by
          such party in writing to the other.

         

        (i)            Benefit and Binding Effect.  This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal representatives.  The
          Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.

         

        (j)            Counterparts.  For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
          which shall constitute one and the same document.

         

        (k)           Integration.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning
          such subject matter, including but not limited to, any written or oral offer letter or consulting or service agreement between the parties that provides for the issuance of equity in the Company.

         

        6.          Dispute Resolution.

         

        (a)            Except as provided below, any dispute arising out of or relating to the Plan or the Shares, this Agreement, or the breach,
            termination or validity of the Plan, the Shares or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the “J.A.M.S.
            Rules”).  The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1 - 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.  The place of
            arbitration shall be Boston, Massachusetts.

         

        
          48

          
            

        

        (b)          The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.  In connection with the arbitration
            proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses.  In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her
            discretion allow additional depositions upon good cause shown by the moving party.  However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.  In connection with any
            arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be
            introduced at the arbitration or considered or used by a party’s witness or expert.  The arbitrator’s decision and award shall be made and delivered within six months of the selection of the arbitrator.  The arbitrator’s decision shall set
            forth a reasoned basis for any award of damages or finding of liability.  The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each
            party hereby irrevocably waives any claim to such damages.

         

        (c)          The Company, the Grantee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such
            party will participate in the arbitration in good faith.  This Section 6 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may
            proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm.

         

        (d)          Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or
            decision in any such proceeding, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above
            named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding
            is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an
            enforcement of the judgment of any such court.  Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.  Each Party agrees that its, his or her submission to jurisdiction and its, his
            or her consent to service of process by mail is made for the express benefit of each other Party.  Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on
            the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction.

         

        [SIGNATURE PAGE FOLLOWS]

         

        

        
          49

          
            

        

        The foregoing Restricted Stock Agreement is hereby accepted and the terms and conditions thereof are hereby agreed to by the undersigned as of the date of purchase of Shares above written.

         

        

        	 	
                DISC MEDICINE, INC.

              
	 	 
	 	
                By:

              	 
	 	 	
                Name:

              	 
	 	 	
                Title:

              	 
	 	 	 	 
	 	
                Address:

              
	 	 
	 	 
	 	 
	 	 

         

        

        The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section 9 thereof and understands that the Shares granted hereby are subject to the terms of the Plan and of this Agreement.  This
          Agreement is hereby accepted, and the terms and conditions of the Plan, the Award Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 6 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as
          of the date first above written.

         

        

        	 	
                GRANTEE:

              
	 	 
	 	 
	 	
                Name:

              	 
	 	 	 
	 	
                Address:

              	 
	 	 
	 	 
	 	 
	 	 

        

        

        
          50

          
            

        

        
          	
                  
                    [SPOUSE’S CONSENT3

                    I acknowledge that I have read the

                    foregoing Restricted Stock Agreement

                    and understand the contents thereof.

                     ]

                

        

        

        

        3 A spouse’s consent is required only if the Grantee’s state of residence is one of the following community property states: 
          Arizona, California, Idaho, Louisiana, New Mexico, Nevada, Texas, Washington and Wisconsin.

         

        
          51

          
            

        

        DISC MEDICINE, INC.

         

        PHANTOM STOCK APPRECIATION RIGHT AGREEMENT

         

        THIS PHANTOM STOCK APPRECIATION RIGHT AGREEMENT (this “Agreement”) is entered into and effective as of __________, 202__ (the “Effective Date”) by and between Disc Medicine, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), and _______________ (the “Grantee”).

         

        R E C I T A L S

         

        WHEREAS, Grantee is a service provider to the Company; and

         

        WHEREAS, in consideration of Grantee’s service to the Company, the Company desires to provide Grantee with the opportunity to earn additional compensation in the form of a bonus tied to the value of the Common Stock
          in connection with a Sale Event (as defined in the Plan).

         

        NOW THEREFORE, the Parties agree as follows:

         

        
          
 

         

        

        SECTION 1

         

        DEFINITIONS

         
          

         

        

        1.1          Specific Definitions.  As used in this Agreement:

         

        Common Stock shall mean the common stock of the Company.

         

        Parties shall mean the Company and the Grantee.

         

        Plan shall mean the Disc Medicine, Inc. 2017 Equity Incentive Plan or any successor plan, the terms of which are incorporated herein by reference.

         

        
          
            

           

        

        SECTION 2

         

        ECONOMIC INTEREST

         
          
            

        

         

        2.1         Issuance of Economic Interest.  Subject to the provisions of this Agreement the Company hereby agrees to pay to the Grantee the amount the
          Grantee would be entitled to receive upon completion of a Sale Event had the Grantee been issued an option to purchase ___________ shares of Common Stock as of the Effective Date (and, for clarification purposes, net of the applicable $         
               exercise price per share that would have applied to such option (the “Phantom Exercise Price Per Share”)) (the “Phantom Common Stock”).  The Parties expressly
          intend that Phantom Common Stock shall consist solely of an economic interest and shall not have any other rights of Common Stock under the Plan or otherwise. The Phantom Common Stock is subject to a time-based vesting condition (the “Time Condition”) described in paragraph 2.2 below.

         

        

        
          
            

        

        
        2.2        Time Condition.  The Time Condition shall be satisfied as to 25% of the shares of Phantom Common Stock awarded hereunder on the first
          anniversary of the Effective Date and as to the remainder of the shares of Phantom Common Stock in equal pro rata amounts on each monthly anniversary thereafter through the fourth anniversary of Effective Date, provided that the Grantee maintains
          continuously a Service Relationship (as defined in the Plan) by the Company on each such anniversary date.

         

        2.3        Vesting Date.  To the extent the Phantom Common Stock has not satisfied the Time Condition as of the 10-year anniversary of this Agreement,
          such Phantom Common Stock shall expire on such date and be of no further force or effect.

         

        2.4          Payments.

         

        (a)          The Grantee shall be entitled to receive one or more cash payments from the Company in respect of his or her vested shares of Phantom Common Stock in connection with or following a
          Sale Event. The cash payment per vested share of Phantom Common Stock shall be determined by the Company in its sole and absolute discretion, based upon the consideration received in connection with the Sale Event by the Common Stockholders, and,
          except as set forth in paragraph 2.4(b) shall be net of the Phantom Exercise Price Per Share.

         

        (b)          The Grantee shall be entitled to receive payments from the Company in respect of the Phantom Common Stock only to the extent that the Grantee has continuously maintained a Service
          Relationship with the Company from the Effective Date to the date of the Sale Event.  In the event of a termination of Grantee’s Service Relationship with the Company for any reason other than a termination by the Company for cause (as determined
          by the Company in its sole and absolute discretion), the Grantee may pay the Phantom Exercise Price for any vested portion of Grantee’s Phantom Common Stock in cash to the Company within ninety (90) days of such termination and, in that event,
          Grantee shall be entitled to receive the payment contemplated by Section 2.1 for such vested Phantom Common Stock upon a Sale Event prior to the Expiration Date, notwithstanding the earlier termination of Grantee’s Service Relationship with the
          Company, and any such payments shall include and shall not be net of the Phantom Exercise Price Per Share.

         

        2.5          Tax Payments.  Grantee acknowledges and agrees that (a) payments made to the Grantee pursuant to the Grantee’s Service Relationship with the
          Company shall be subject to withholding of applicable taxes, (b) the Grantee shall be obligated to report as income all compensation received by the Grantee pursuant to this Agreement and (c) the Grantee shall pay all applicable taxes due on such
          compensation in the case of under-withholding by the Company.

         

        
          
            

           

        

        SECTION 3

         

        RELATIONSHIP BETWEEN

        GRANTEE AND COMPANY

         

        
          
            

           

        

        3.1          Not a Stockholder; No Right of Service Relationship.  The Grantee shall not, by virtue of entering into this Agreement and receiving Phantom
          Common Stock, be deemed a stockholder of the Company.  The Grantee hereby acknowledges and agrees that he or she is not a stockholder of the Company and that the Company is not under any obligation to make the Grantee a stockholder of the Company
          in the future.  Nothing contained in this Agreement or in the grant of Phantom Common Stock shall limit, restrict or modify the Company’s right to terminate the Service Relationship of the Grantee.

         

        

        
          -2-

          
            

        

        3.2        No Management Rights.  The Grantee shall not, by virtue of entering into this Agreement and receiving a Phantom Common Stock, hold any
          non-economic rights in respect of the Company.  Without limitation on the preceding sentence, the Grantee shall have no right to participate in the management, control or operation of the Company or its business, act for the Company, bind the
          Company under agreements or arrangements with third parties, or vote on Company matters.  The Grantee shall not have any right to receive or review the books, records, reports or other information of the Company.

         

        
          
            

           

        

        SECTION 4

         

        GENERAL PROVISIONS

        
           

          
            

           

        

        4.1       Entire Agreement.  This Agreement contains the entire understanding among the Parties, and supersedes any prior written or oral agreement
          between them, respecting the subject matter hereof.  There are no representations, agreements, arrangements or understandings, oral or written, among the Parties relating to the subject matter hereof which are not fully expressed in this
          Agreement.

         

        4.2          Amendment.  This Agreement may be amended, in whole or in part, only through a written amendment executed by both Parties.

         

        4.3          Counterparts.  This Agreement may be executed in any number of counterparts and, when so executed, all of such counterparts shall constitute a
          single instrument binding upon both Parties notwithstanding the fact that both Parties are not signatory to the original or to the same counterpart.

         

        4.4        No Third Party Beneficiaries.  The provisions of this Agreement are not intended to be for the benefit of or enforceable by any third party.

         

        4.5          Notices, Consents, Elections, Etc.  All notices, consents, agreements, elections, amendments and approvals provided for or permitted by this
          Agreement shall be in writing.  Except as otherwise specifically provided in this Agreement, notice to a Party shall be deemed duly given upon the earliest to occur of the following: (i) personal delivery to such Party, to the address set forth
          on the signature pages hereto for such Party, or to any other address which such Party has provided to the other Party for purposes of this Section 4.5; (ii) the Close of Business on the third day after being deposited in the United States mail,
          registered or certified, postage prepaid and addressed to such Party at the address set forth on the signature pages for such Party, or at any other address which such Party has provided to the other Party for purposes of this Section 4.5; (iii)
          the Close of Business on the first business day after being deposited in the United States with a nationally recognized overnight delivery service, with delivery charges prepaid, addressed as provided in the preceding clause, and marked for next
          business day delivery; or (iv) actual receipt by such Party via any other means (including public or private mail, electronic mail, facsimile, telex or telegram); provided, however, that notice sent to a Party via electronic mail
          shall be deemed duly given at the earlier of: (x) the time sent (unless such Party previously elected via notice to the sender to render this clause (x) inapplicable to such Party); and (y) the time when actually received and opened by such
          Party.

          

        

        
          -3-

          
            

        

        4.6         Waiver.  Except as specifically provided in this Agreement, no failure or delay by any Party in exercising any right, power or privilege under
          this Agreement shall operate as a waiver thereof.  Any actual waiver shall be contained in a writing signed by the Party against whom enforcement of such waiver is sought.

         

        4.7        Severability.  In the event that any provision of this Agreement is determined to be invalid or unenforceable, such provision shall be deemed
          severed from the remainder of this Agreement and replaced with a valid and enforceable provision as similar in intent as reasonably possible to the provision so severed, and shall not cause the invalidity or unenforceability of the remainder of
          this Agreement.

         

        4.8         Code Section 409A. It is the intent that the Phantom Common Stock
            shall be either exempt from or compliant with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and any successor Code, and related rules, regulations and interpretations, and the Phantom Common
            Stock shall be interpreted, construed and operated to reflect this intent. Solely for purposes of Section 409A of the Code, each payment on (or following) a Vesting Date shall be considered a separate payment. The Company reserves the right, to
            the extent the Company deems necessary or advisable in its sole discretion, to unilaterally amend or modify this Phantom Common Stock Agreement as may be necessary to ensure that the Phantom Common Stock qualifies for the exemption from, or
            complies with the requirements of, Section 409A or to mitigate any additional tax, interest and/or penalties or other adverse tax consequences that may apply under Section 409A if compliance is not practical. Nothing in this Phantom Common
            Stock Agreement shall provide a basis for any person to take any action against the Company or any parent or subsidiary based on the tax treatment of any amounts paid under the Phantom Common Stock, and neither the Company nor any parent or
            subsidiary will have any liability under any circumstances to Grantee or any other party regarding the tax treatment of the Phantom Common Stock or for any action taken by the Committee with respect thereto.

         

        4.9        Governing Law.  The interpretation and enforceability of this Agreement and the rights and liabilities of the Parties as such shall be governed
          by the laws of the State of Delaware, without regard to conflict of law principles, and as such laws are applied in connection with agreements entered into and wholly performed upon in Delaware by residents of Delaware.  To the maximum extent
          permitted by applicable law, the provisions of this Agreement shall supersede any contrary provisions of applicable law.

         

        4.10       Restriction on Transfers and Assignments.  No Party may pledge, assign, or in any other manner transfer this Agreement or any right or interest
          herein or arising hereunder, and any attempted pledge, assignment, or other transfer shall be null and void.

         

        [Remainder of this page intentionally left blank; signature page follows.]

         

        
          -4-

          
            

        

        IN WITNESS WHEREOF, the Parties have executed this PHANTOM STOCK APPRECIATION RIGHT AGREEMENT as of the date first above written.

         

        

        	
                Company:

              	 
	 	 	 
	
                DISC MEDICINE, INC.

              	 
	 	 	 
	
                By:

              	 	 
	
                Name:

              	 	 
	
                Title:

              	 	 
	 	 	 
	
                Grantee:

              	 
	 	 	 
	 	 
	
                Name:Exhibit 10.10

  

  

    December 29, 2022

    

    

    Brian Piekos

    

    

    Re:          Notice of Termination, Separation Agreement and Release

    

    

    Dear Brian:

     

    As discussed, this letter confirms the terms of your separation from employment at Gemini Therapeutics, Inc. (the “Company”).1  As we agreed, your employment will end on December 29, 2022 (the “Separation Date”), which follows the occurrence of a Change in Control (as defined in the Employment Agreement (as defined below)).  Consistent with the
      terms of your Employment Agreement with the Company, dated February 4, 2021 (the “Employment Agreement”), you shall be deemed to have resigned from all officer positions that you hold with the Company upon the Separation Date.  Furthermore, in
      accordance with your Employment Agreement, the Company will provide you with certain Severance Benefits (as defined below) following the end of your employment if you sign and return this letter agreement (the “Agreement”) by February 3, 2023
      (but no earlier than the Separation Date), do not revoke the Agreement (as described below), and comply with the terms and conditions of the Agreement.  As required under Section 3(f) of the Employment Agreement, this Agreement serves as a Notice of
      Termination pursuant to Section 3(d) of the Employment Agreement.

     

    In the interest of clarity, the following terms and conditions apply in connection with the end of your employment and regardless of whether you enter into the Agreement:

     

    	

          	•	
            The Company will pay your salary and any accrued but unused vacation days to which you are entitled through the Separation Date.

          

     

    	

          	•	
            You will be able to continue group healthcare insurance coverage after the Separation Date under the law known as “COBRA,” subject to eligibility requirements.  Any COBRA continuation will be at your own cost, except as otherwise set forth
              herein if this Agreement becomes effective.

          

     

    	

          	•	
            Your eligibility to participate in any other employee benefit plans and programs of the Company will cease on or after the Separation Date in accordance with applicable benefit plan or program terms and practices.

          

     

    	

          	•	
            The Company will reimburse you for any outstanding, reasonable business expenses you have incurred on the Company’s behalf through the Separation Date in accordance with the Company’s expense reimbursement policy, after the Company’s
              timely receipt of appropriate documentation pursuant to such policy.

          

     

    	

          	•	
            You will cease vesting in all of your stock options and other stock-based awards subject to vesting (the “Equity Awards”) as of your Separation Date in accordance with the terms of the Equity Documents (as defined below), and you
              may exercise any vested portion of your options in accordance with the time limits and subject to the terms of the applicable Equity Award agreement and equity plan (the “Equity Documents”) unless otherwise set forth herein if this
              Agreement becomes effective.

          

     

    

    
      
1 Except for the obligations set forth through the end of Section 2 hereof, which shall be the sole obligation of Gemini Therapeutics, whenever the term “the
      Company” is used in this Agreement, it shall be deemed to include Gemini Therapeutics, Inc., Gemini Therapeutics Sub, Inc., and any other related companies (including, without limitation, any divisions, affiliates, parents and subsidiaries of any of
      Gemini Therapeutics), and its and their respective officers, directors, employees, agents, successors and assigns.

    

    

    
      1

      
        

    

    	

          	•	
            In accordance with Section 15 of the Employment Agreement, your obligations set forth in Sections 8 and 9 in the Employment Agreement will continue after the Separation Date, except as otherwise set forth herein if this Agreement becomes
              effective.

          

     
    	

          	•	
            In accordance with Section 30 of the Employment Agreement, your obligations with respect to confidentiality and assignment of inventions, as set forth in the agreement you signed when your employment began relating to such matters (the “Original
                Confidentiality Agreement”), will continue after the Separation Date.

          

     

    In addition to the above-described terms, you will be eligible to receive the Severance Benefits described in Section 2, provided you timely enter into, do not revoke, and comply with this
      Agreement.

     

    The remainder of this letter proposes the Agreement between you and the Company.  With those understandings, you and the Company agree as follows:

     

    1.         Conditions.  To receive the benefits described in this Agreement, you must (i) timely
      enter into, not revoke, and comply with this Agreement and (ii) between now and the Separation Date, work with the Company to ensure the professional transition and wind down of your duties (the “Conditions”).

     

    2.        Severance Benefits.  If you satisfy the Conditions, then the
      Company will provide you with the following “Severance Benefits” following the Separation Date:

     

    (a)          Severance Pay.  The Company will pay you an amount equal to the sum of (i) (12) months of your
      current base salary plus (ii) your Target Bonus (as defined in the Employment Agreement) for the current year, less standard payroll deductions and withholdings (the “Severance Pay”).  The Severance Pay will be paid out in a lump sum within
      thirty (30) days after the Effective Date (as defined below) of this Agreement.

     

    (b)          Equity Awards.  Notwithstanding anything to the contrary in any applicable Equity Document, all
        unvested stock options and other stock-based awards subject to vesting held by you shall immediately accelerate and become fully exercisable or nonforfeitable as of the Effective Date of this Agreement (and any termination or forfeiture of the
        unvested portion of such awards that would otherwise occur on the Separation Date in the absence of this Agreement will be delayed until the Effective Date and will only occur if the vesting pursuant to this provision does not occur due to the
        absence of the Agreement becoming fully effective within the time period set forth herein).

     

    (c)          Health Benefits Continuation.  If you timely and properly elect to receive benefits under
      COBRA, then the Company will pay all required premiums on a monthly basis for the same level of group healthcare coverage as in effect for you on the Separation Date until the earliest of the following:  (i) the twelve (12)-month anniversary of the
      Separation Date; (ii) your eligibility for group healthcare coverage through other employment; or (iii) the cessation of your continuation rights under COBRA (the “Health Benefits Continuation Period”); provided, however, if the Company
      determines it cannot pay such amounts without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company will convert such payments to payroll payments directly to you for the
      time period specified above. Such payments shall be subject to tax- related deductions and withholdings and paid on the Company’s regular payroll dates.  You agree to notify the Company promptly if you become eligible for group healthcare coverage
      through another employer.  You may continue COBRA coverage after the end of the Health Benefits Continuation Period at your own expense for the remainder of the COBRA continuation period, subject to continued eligibility.

     

    
      2

      
        

    

    (d)          Continued Vesting and Extended Exercise Period.  The Company shall extend the exercise period with
        respect to your vested stock options until the earlier of (i) the original ten (10) year expiration date for such vested stock options as provided in the applicable Equity Documents, or (ii) one (1) year from the Separation Date.

     

    3.          Restrictive Covenants.

     

    (a)          Reaffirmation of Continuing Obligations.  You hereby reaffirm all of your continuing obligations to the Company as set forth in Section 8
      of the Employment Agreement, including your confidentiality, invention assignment, and non-solicitation obligations, which survive your separation from employment and remain in full force and effect.

     

    (b)          Non-Competition.  You and the Company acknowledge and agree that the non-competition restriction in Section 8(h)(iii) of the Employment
      Agreement shall not apply, and that you are not entitled to any Garden Leave Pay pursuant to the terms of Section 8(h)(iii) of the Employment Agreement.  However, you agree that in connection with your separation from employment and in order to
      protect the Company’s Proprietary Information (as defined in the Employment Agreement), goodwill, and other legitimate business interests, for a period of: (i) one (1) year following the Separation Date, or (ii) two (2) years following the Separation
      Date if you breach your fiduciary duty to the Company or if you have unlawfully taken, physically or electronically, property belonging to the Company, you shall not directly or indirectly, whether as owner, partner, shareholder, director, manager,
      consultant, agent, employee, co-venturer or otherwise, anywhere in the world, engage or otherwise participate in any business that develops, manufactures or markets any products, or performs any services, that are competitive with the products or
      services of the Company, including, without limitation, any products or services that target amino acid homeostasis for therapeutic and health purposes via the use of amino acid modalities, or products or services that the Company or its affiliates
      has under development or were the subject of active planning at any time during your employment.  You acknowledge this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other
      covenants in this Agreement or the Employment Agreement.

     

    You agree that in the event you breach any of your obligations described in this Section 3 and/or the restrictions under this Section 3, the remedies set forth in Section 12 of the Employment Agreement shall be
      available to the Company.

     

    4.          Return of Property.  You acknowledge and agree you are required to return all Company
      property in your possession to the Company; provided, however, you shall be permitted to keep your Company-owned laptop, monitors, keyboards, and docking stations after the Company has removed all Company materials, information and other Proprietary
      Information from such hardware.  Accordingly, by signing below, you acknowledge and agree you will comply with Section 8(f) of the Employment Agreement by returning to the Company on or before the Separation Date (or sooner if requested by the
      Company) all Company property, including, without limitation, all files, reports, documents or other materials containing or pertaining to Proprietary Information (as defined in the Employment Agreement) and to your work (and all reproductions
      thereof).  Simultaneous with your return of all of the foregoing, you commit to deleting and finally purging any duplicates of files or documents that may contain Company information from any non-Company computer or other device that remains your
      property after the Separation Date.  In the event you discover that you continue to retain any such information or property, you shall return it to the Company immediately.

     

    
      3

      
        

    

    5.          Non-Disparagement.  Subject to Sections 8 and 10 of this Agreement, you
      agree to take no action or make any statements, written or oral, that are disparaging about or adverse to the business interests of the Company or its employees, directors, officers, agents, products, or services.  This non-disparagement obligation
      shall not apply to truthful testimony in a legal proceeding or pursuant to a subpoena or to communication with any Government Agency (as defined below) or participation in any investigation or proceeding that may be conducted by any Government
      Agency.

     

    6.          Communications.  You will not communicate about your departure with anyone until after
      the Board has made a public written announcement about your departure (the “Company Announcement”); provided that you may communicate with your tax advisors, attorneys and spouse about your departure before the Company Announcement, provided
      further that you first advise such persons not to reveal information about your departure and each such person agrees.  The Company agrees that, unless otherwise required by applicable law or regulation as determined by the Company in its reasonable
      good faith discretion, the Company shall give you an opportunity to review the Company Announcement prior to its publication.  Once the Company has made the Company Announcement, you agree to limit any communications regarding your departure to
      statements consistent with the Company Announcement.

     

    7.          Release of Claims.  In consideration for, among other terms, the opportunity to
      receive the Severance Benefits, to which you acknowledge you would otherwise not be entitled, you voluntarily release and forever discharge the Company, its affiliated and related entities, its and their respective predecessors, successors and
      assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal
      capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when you sign this Agreement, you
      have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees.  This release includes, without limitation, all Claims:

     

    	

          	•	
            relating to your employment by the Company and the end of your employment with the Company;

          

    	

          	•	
            of wrongful discharge or violation of public policy;

          

    	

          	•	
            of breach of contract;

          

    	

          	•	
            of defamation or other torts;

          

    	

          	•	
            of retaliation or discrimination under federal, state, or local law (including, without limitation, Claims of discrimination or retaliation under the Age Discrimination in Employment Act; the Americans with Disabilities Act; Title VII of
              the Civil Rights Act of 1964; and the Massachusetts Fair Employment Practices Act);

          

    	

          	•	
            under the Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the Massachusetts Labor and Industries Act, the Massachusetts Payment of Wages Act, the Massachusetts Privacy Act, the Massachusetts Parental Leave Act, the
              Massachusetts Domestic Violence Leave Act, the Massachusetts Sick Leave Act, and the Massachusetts Paid Family and Medical Leave Act;

          

    	

          	•	
            under any other federal or state statute (including, without limitation, Claims under the Fair Labor Standards Act);

          

    	

          	•	
            for wages, bonuses, incentive compensation, stock, stock options, vacation pay, or any other compensation or benefits, either under the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, §§ 148-150C, or otherwise; and

          

    	

          	•	
            for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees.

          

    

    

    
      4

      
        

    

    You agree and acknowledge you are waiving and releasing any claims for unpaid wages of any type you may have against the Company under the Massachusetts Payment of Wages Act,
      M.G.L. c. 149, § 148 et seq.

     

    Notwithstanding the foregoing or any other provision of this Agreement:  (i) you are not releasing the Company from any obligation expressly set forth in this Agreement; (ii) your right to file a
      claim with the Equal Employment Opportunity Commission (“EEOC”), National Labor Relations Board, or similar state agencies is expressly preserved, provided, however, if you file such a claim, you waive the right to recover monetary damages and
      any other relief personal to you in connection with such claim; (iii) you are not waiving claims that cannot be waived by law, such as claims for workers’ compensation or unemployment benefits; (iv) you retain rights to any vested benefits, such as
      vested equity or pension or retirement benefits, the rights to which are governed by the terms of the applicable plan documents; (v) you retain the right to participate in any investigation by any government agency charged with enforcement of any
      law; (vi) you are not waiving or releasing claims arising solely after the execution of this Agreement; (vii) you are not waiving or releasing non-termination related claims under the Employee Retirement Income
        Security Act (29 U.S.C. § 1001 et seq.), as amended; and (viii) you are not waiving or releasing any rights and/or claims you may have under COBRA.

     

    8.          Protected Disclosures and Other Protected Actions.  Nothing contained in this
      Agreement limits your ability to file a charge or complaint with any federal, state, or local governmental agency or commission (a “Government Agency”).  In addition, nothing contained in this Agreement limits your ability to communicate with
      any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, nor does anything contained in this Agreement apply to truthful testimony in litigation.  If you file any charge or
      complaint with any Government Agency and if the Government Agency pursues any claim on your behalf, or if any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized relief (either individually or
      as part of any collective or class action).  Nothing herein, however, limits your right to receive an award under the SEC Whistleblower Program.

     

    9.         Tax Treatment.  The Company shall undertake to make deductions, withholdings and tax
      reports with respect to payments and benefits under this Agreement to the extent it reasonably and in good faith determines it is required to make such deductions, withholdings and tax reports.  Nothing in this Agreement shall be construed to require
      the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.  The parties intend that payments under this Agreement will be
      exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).  To the extent that any provision of this Agreement is ambiguous as to its exemption from or compliance with Section 409A of the Code, the
      provision shall be read in such a manner so that all payments hereunder are exempt from or comply with Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
      Section 1.409A 2(b)(2).  The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code
      but do not satisfy an exemption from, or the conditions of, such Section.

     

    10.       Consideration Period and OWBPA.  It is the Company’s desire and intent to make certain
      you fully understand the provisions and effects of this Agreement.  To that end, the Company hereby advises you in writing to consult with legal counsel for the purpose of reviewing the terms of this Agreement, and you are being given the opportunity
      to do so.  Because you are over 40 years of age, you are granted specific rights under the Older Workers Benefit Protection Act (“OWBPA”), which prohibits discrimination on the basis of age.  Among other things, the release set forth in Section
      7 is intended to release any rights you may have against the Company alleging discrimination on the basis of age under the Age Discrimination in Employment Act (“ADEA”), the OWBPA and state and local laws.  You acknowledge and understand
      the release in Section 7 does not cover rights or claims under the ADEA that may arise after the date you sign this Agreement.

     

    

    
      5

      
        

    

    Consistent with the provisions of OWBPA, you have been provided the opportunity to consider this Agreement for at least forty-five (45) days from your receipt of this Agreement before signing it (the
      “Consideration Period”).  You and the Company agree that any changes to this Agreement, whether material or immaterial, following your receipt of this Agreement do not restart or otherwise affect the Consideration Period.  Furthermore,
      consistent with OWBPA and M.G.L. c. 149, s. 24L, you may revoke your assent to this Agreement if, within seven (7) business days after the date you sign this Agreement, you deliver a written notice of revocation to the Company.  To be effective, such
      notice of revocation must be emailed within the seven (7)-business day period to the Vice President of Legal Affairs.  On the eighth (8th) business day following your
      execution of this Agreement without your revocation, it will become final and binding on all parties (the “Effective Date”).

     

    In accordance with the provisions of OWBPA, attached to this Agreement as Attachment A is a description of (i) any class, unit or group of individuals covered by the program of severance benefits
      that the Company has offered to you, and any applicable time limits regarding such severance benefit program; and (ii) the job titles and ages of all individuals selected for such severance benefit program, and the job titles and ages of all
      individuals in the same job classification or organizational unit who were not selected for such severance benefit program.

     

    Also, consistent with the provisions of the OWBPA and other federal discrimination laws, nothing in the release in Section 7 shall be deemed to prohibit you from challenging the validity of
      this release under the federal age or other discrimination laws (the “Federal Discrimination Laws”) or from filing a charge or complaint of age or other employment related discrimination with the EEOC, or from participating in any
      investigation or proceeding conducted by the EEOC.  However, the release in Section 7 does prohibit you from seeking or receiving monetary damages or other individual-specific relief in connection with any such charge or complaint of age or
      other employment-related discrimination.  Further, nothing in the release in Section 7 or this Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of
      this Agreement constitutes a full release of any individual rights under the Federal Discrimination Laws, or the Company’s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under
      this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under the Federal Discrimination Laws.

     

    By signing this Agreement, you acknowledge and agree: (i) but for providing the waiver and release in Section 7, you would not be receiving the Severance Benefits being provided to you under
      the terms of this Agreement; (ii) you understand the various claims you are entitled to assert under the laws set forth above; (iii) you have read this Agreement carefully and understand all its provisions; and (iv) the Company is hereby advising you
      to consult with an attorney before signing this Agreement and to the extent you desired, you availed yourself of this right.

     

    11.          Other Provisions

     

    (a)          Termination of Payments.  In the event you fail to comply with any of your obligations under this Agreement, in addition to any other
      legal or equitable remedies it may have for such breach, the Company shall have the right to discontinue providing you with the Severance Benefits.  Any such consequences of a breach by you will not affect the release or your continuing obligations
      under this Agreement or the Employment Agreement.

     

    
      7

      
        

    

    (b)          Absence of Reliance.  In signing this Agreement, you are not relying upon any promises or representations made by anyone at or on behalf
      of the Company, except as set forth in this Agreement.

     

    (c)          Jurisdiction.  You and the Company hereby agree the state and federal courts in the Commonwealth of Massachusetts shall have the
      exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim of a violation of this Agreement.  With respect to any such court action, you submit to the jurisdiction of such courts and you
      acknowledge venue in such courts is proper.

     

    (d)          Governing Law; Interpretation.  This Agreement shall be interpreted and enforced under the laws of the Commonwealth of Massachusetts,
      without regard to conflict of law principles.  In the event of any dispute, this Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning, and not to be construed strictly for or against
      either you or the Company or the “drafter” of all or any portion of this Agreement.

     

    (e)          Enforceability.  If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of
      this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is
      so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

     

    (f)          Waiver; Amendment.  No waiver of any provision of this Agreement shall be effective unless made in writing and signed by the waiving
      party.  The failure of a party to require the performance of any term or obligation of this Agreement, or the waiver by a party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a
      waiver of any subsequent breach.  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.

     

    (g)          Entire Agreement.  This Agreement constitutes the entire agreement between you and the Company with respect to the subject matter hereof,
      and supersedes all prior agreements or understandings, both written and oral, between you and the Company with respect to the subject matter hereof, but does not in any way merge with or supersede the surviving provisions of the Original
      Confidentiality Agreement, the Employment Agreement, or the Equity Documents, which agreements and obligations shall supplement, and shall not limit or be limited by, this Agreement.

     

    (h)          Counterparts.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken
      to be an original, but all of which together shall constitute one and the same document.  Electronic and pdf signatures shall be deemed to have the same legal effect as originals.

     

    [Signature Page Follows]

     

    
      7

      
        

    

    
    

    

    Please indicate your agreement to the terms of this Agreement by signing and returning to the Vice President of Legal Affairs via PDF by the date set forth above.

     

    Very truly yours,

     

    Gemini Therapeutics, Inc.

       

    	
            By:

          	
            /s/ Georges Gemaye

          	 	
            December 29, 2022

          	 
	
            Name:

          	
            Georges Gemayel, Ph.D.

          	 	
            Date

          	 
	
            Title:

          	
            Executive Chair

          	 	 	 

    

    

    Enclosure (Employment Agreement)

    

    

    This is a legal document.  Your signature will commit you to its terms.  By signing below, you acknowledge the Company has advised you to consult with counsel prior to entering into this Agreement, you have carefully
      read and fully understand all of the provisions of this Agreement, and you are knowingly and voluntarily entering into this Agreement.

     

    	
            /s/ Brian Piekos

          	 	
            December 29, 2022

          	 
	
            Brian Piekos

          	 	
            Date

          	 

     

    

    

    

  

  8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]